# Chapter 116: Stimulant Withdrawal

# The Biological and Neurological Basis of Stimulant Withdrawal

## Introduction

Stimulant withdrawal is a substance-induced disorder characterized by a constellation of distressing physiological and psychological symptoms that emerge following the cessation or significant reduction of chronic stimulant use (Daley & Douaihy, 2019; Thompson & Weber, 2021). Stimulants, a class of sympathomimetic substances including cocaine, amphetamines, and cathinones, exert their primary effects by augmenting monoaminergic neurotransmission, particularly dopamine, norepinephrine, and serotonin (Graddy & Rastegar, 2025; Snyder, 2019). Chronic use leads to significant neuroadaptations in these systems as the brain attempts to maintain homeostasis in the face of persistent drug-induced overstimulation (Koob et al., 2015; Roberts & Koob, 1997). When the drug is removed, these neuroadaptive changes are unmasked, resulting in a state of neurochemical imbalance that manifests as the withdrawal syndrome (Koob, 2020).

The clinical presentation of stimulant withdrawal is often described as a "crash," marked by a predictable sequence of events (Estroff & Gold, 1985). The primary features include dysphoria, fatigue, profound anhedonia (the inability to experience pleasure), psychomotor changes (either agitation or retardation), and significant sleep disturbances such as insomnia or hypersomnia (Graddy & Rastegar, 2020; 2025; Thompson & Weber, 2021). Additional symptoms can include anxiety, irritability, vivid and unpleasant dreams, increased appetite, and intense drug craving (Graddy & Rastegar, 2020; Thompson & Weber, 2021; Daley & Douaihy, 2019). While not typically associated with the severe, life-threatening physical manifestations seen in alcohol or sedative-hypnotic withdrawal, stimulant withdrawal can produce significant psychiatric symptoms, including severe depression and suicidal ideation, which may necessitate hospitalization (Thompson & Weber, 2021; Thompson & Weber, 2021; Thompson & Weber, 2021).

Understanding the biological and neurological underpinnings of this syndrome is critical for developing effective treatments and for conceptualizing stimulant use disorder as a chronic, relapsing brain disease (Koob, 2020; Koob et al., 2015). The withdrawal state is not merely a return to baseline but represents a distinct, allostatic state characterized by a negative emotional condition that powerfully drives relapse (Koob, 2020; Vendruscolo & Koob, 2019). This chapter will explore the neurobiological basis of stimulant withdrawal, synthesizing evidence across multiple domains. We will examine the profound dysregulation of key neurotransmitter systems, the involvement of specific brain regions and neural circuits, and the role of cellular and molecular mechanisms of neuroplasticity. Furthermore, we will discuss genetic factors, neuroimaging findings, and the implications of this biological understanding for the development of targeted therapeutic interventions. The symptomatology of stimulant withdrawal significantly overlaps with other psychiatric conditions, such as major depressive disorder and anxiety disorders (Bains et al., 2021; Munir & Takov, 2021). By drawing parallels with the neurobiology of these conditions, a more comprehensive, albeit inferential, model of the withdrawal state can be constructed, acknowledging the complexities and current limitations in the field.

## Neurobiological Systems

The hallmark of stimulant withdrawal is a profound dysregulation across multiple neurobiological systems, primarily those involved in reward, motivation, stress, and mood regulation. Chronic stimulant use forces the brain to adapt to a state of persistent overstimulation, leading to compensatory changes that become pathologically evident upon drug cessation (Koob et al., 2015; Roberts & Koob, 1997). The withdrawal syndrome can be understood as a manifestation of these adaptations, creating a state of negative affect and hypofunction in reward circuits that powerfully motivates relapse (Koob, 2020).

### Neurotransmitter Systems and Neuropharmacology

**The Dopamine System:** The mesocorticolimbic dopamine system is central to the reinforcing effects of all major drugs of abuse, including stimulants (Bannon et al., 2020; Heinz, 2002; Snyder, 2019). Stimulants such as cocaine and amphetamines acutely increase synaptic dopamine concentrations by blocking the dopamine transporter (DAT) or promoting dopamine release, respectively (Graddy & Rastegar, 2025; Snyder, 2019; Uddin et al., 2017). This surge in dopamine in key reward areas like the nucleus accumbens (NAc) is associated with the euphoria and reinforcement that drive initial and continued use (Snyder, 2019; Beninger, 2018).

Chronic exposure to high levels of synaptic dopamine leads to significant neuroadaptations. A key compensatory mechanism is the downregulation of dopamine D2 receptors, which has been observed in various contexts of dopaminergic dysfunction (Ereshefsky et al., 1990). This reduction in D2 receptor density and sensitivity contributes to a state of dopamine hypofunction during withdrawal (Heinz, 2002; Volkow & Wolf, 1991). This hypo-dopaminergic state is thought to be a primary driver of the core withdrawal symptoms of anhedonia, dysphoria, and lack of motivation (Koob, 2020; Heinz, 2002). The loss of interest and pleasure seen in withdrawal (Graddy & Rastegar, 2020) parallels the anhedonia that is a core feature of major depressive disorder, a condition also linked to dysregulation in monoaminergic systems (Bains et al., 2021; Kennedy, 2008). The experience of craving, a central feature of addiction and withdrawal, is also mediated by brain activation in reward-related regions such as the amygdala (Daley & Douaihy, 2019). The compulsive drug-seeking behavior characteristic of addiction is believed to arise from these enduring, drug-induced neuroadaptations within the mesocorticolimbic dopamine system (Koob et al., 2015; Vanderschuren, 2008; Antonio & Alfredo, 2012).

Furthermore, the psychosis that can occur with high-dose stimulant use (Bell, 1973; McKetin, 2018) and, more rarely, during withdrawal (Weibel et al., 2013), is strongly linked to excess dopamine activity, providing a model for psychosis in schizophrenia (Moncrieff, 2009; Snyder, 2019). The therapeutic action of antipsychotic drugs, which block dopamine D2 receptors, underscores this connection (Ereshefsky et al., 1990; Ghaemi, 2018). The irritability and aggression sometimes seen in withdrawal may also be related to dysregulated dopaminergic transmission (Eatmon & Daniel, 2014).

**The Serotonin and Norepinephrine Systems:** While dopamine is central, stimulants also potently affect serotonin (5-HT) and norepinephrine (NE) systems (Graddy & Rastegar, 2025; Cruickshank & Dyer, 2009). MDMA ('ecstasy'), for instance, has a particularly strong effect on serotonin release and reuptake inhibition (Parrott, 2001; Chummun et al., 2010). Chronic use of such agents can lead to long-term depletion of brain serotonin stores, which is believed to contribute to subsequent mood and cognitive problems (Parrott, 2001; Molero‐Chamizo, 2005). The withdrawal phase from stimulants is characterized by symptoms that overlap significantly with major depression, including depressed mood, anhedonia, fatigue, and sleep disturbances (Graddy & Rastegar, 2025; Bains et al., 2021; Kennedy, 2008). This clinical overlap suggests a shared neurobiological substrate, likely involving deficits in serotonin and norepinephrine neurotransmission (Stahl, 2000; Kennedy, 2008). Antidepressant medications, which act by increasing synaptic availability of these monoamines, are often considered in managing the depressive symptoms of withdrawal (Baldessarini, 1989; Fajemiroye, 2016).

The anxiety, agitation, and restlessness common in stimulant withdrawal (Graddy & Rastegar, 2020; Thompson & Weber, 2021) are also linked to dysregulation of the noradrenergic system (Praag, 1998; Kirov, 1989). The locus coeruleus, the brain's primary source of norepinephrine, is heavily involved in arousal and the stress response (Granger & Shelly, 1996). Chronic stimulant use disrupts this system, and withdrawal may lead to a state of noradrenergic hyperactivity, contributing to symptoms of autonomic arousal and anxiety (Hemmingsen et al., 1983; Praag, 1998). This is analogous to the "cholinergic rebound" seen after discontinuation of tricyclic antidepressants, which causes somatic distress and anxiety (Dilsaver et al., 1987). The serotonin syndrome, a potentially life-threatening condition of excessive serotonergic activity caused by drug combinations, highlights the powerful effects of these systems on mental status, autonomic function, and neuromuscular activity (Scotton et al., 2019; Gordon & Leder, 2012), providing a model for the severe autonomic dysregulation that can occur.

**The Glutamate and GABA Systems:** The brain's primary excitatory (glutamate) and inhibitory (gamma-aminobutyric acid, GABA) systems are also critically involved in the neuroadaptations to chronic stimulant use and subsequent withdrawal (Antonio & Alfredo, 2012). Chronic stimulant exposure leads to long-term changes in glutamatergic projections from the prefrontal cortex to the nucleus accumbens, which are thought to mediate craving and relapse (Kalivas et al., 2003; Antonio & Alfredo, 2012). During withdrawal, there is evidence of enhanced function of NMDA glutamate receptors, contributing to a state of neuronal hyperexcitability (Eşel, 2006). This hyperexcitability is a common mechanism across different withdrawal syndromes, including alcohol withdrawal, where it can lead to seizures (Eşel, 2006; Becker & Redmond, 2002).

Simultaneously, the GABA system, which provides inhibitory tone in the brain, also undergoes adaptation. Chronic stimulant use can lead to a hypofunction of GABA receptors during withdrawal (Eşel, 2006). This reduction in inhibitory control, combined with glutamatergic hyperactivity, creates a profound state of central nervous system hyperexcitability (Eşel, 2006; Becker & Redmond, 2002). This imbalance is a core feature of withdrawal from many CNS depressants like alcohol and benzodiazepines, where it manifests as anxiety, insomnia, agitation, and seizures (Thompson & Weber, 2021; Madhavan, 2017; Pétursson, 1994). While seizures are not a hallmark of stimulant withdrawal, the underlying principle of an excitatory/inhibitory imbalance contributes significantly to the psychological symptoms of anxiety, restlessness, and irritability (Graddy & Rastegar, 2025; Thompson & Weber, 2021). The anxiolytic effects of GABA-enhancing agents like benzodiazepines underscore the role of this system in anxiety regulation (Feighner & Boyer, 1989).

### Brain Regions, Neural Circuits, and Functional Connectivity

The behavioral manifestations of stimulant withdrawal arise from altered activity and connectivity within a network of brain regions crucial for reward, motivation, emotion, and executive control.

**The Reward Circuitry:** The mesolimbic pathway, connecting the ventral tegmental area (VTA) to the nucleus accumbens (NAc), is the primary substrate for the rewarding effects of stimulants (Beninger, 2018; Heinz, 2002). Chronic overstimulation of this pathway leads to neuroplastic changes that result in a blunted response to both the drug and natural rewards during withdrawal—a state known as anhedonia (Koob, 2020; Moreau et al., 1995). This hypo-dopaminergic state in the NAc is a key neurobiological correlate of the loss of pleasure and motivation that defines the withdrawal "crash" (Heinz, 2002; Kalivas et al., 2003). Research on behavioral sensitization, a phenomenon where repeated stimulant administration leads to an augmented motor response, has shown that this process involves enduring plasticity in dopamine and glutamate circuits connecting the VTA, NAc, and prefrontal cortex (Kalivas, 2003; Yui et al., 2006). These sensitized circuits are thought to mediate the intense craving and propensity for relapse seen during abstinence (Stewart, 2003).

**The Extended Amygdala and Stress Systems:** The extended amygdala, which includes the central nucleus of the amygdala, the bed nucleus of the stria terminalis, and a portion of the NAc shell, is a critical component of the brain's stress and anti-reward system (Koob, 2020). Chronic drug use leads to a dysregulation of this system, characterized by the recruitment of stress neurotransmitters like corticotropin-releasing factor (CRF) (Koob, 2020; Vendruscolo & Koob, 2019). During withdrawal, this system becomes hyperactive, contributing to the negative emotional state—including dysphoria, anxiety, and irritability—that drives compulsive drug use through a process of negative reinforcement (Koob, 2020; Wand, 2008). Stress is a well-known trigger for relapse, and this is believed to be mediated by the sensitization of these extended amygdala circuits (Stewart, 2003; Anisman & Merali, 1999; Wand, 2008). The anxiety and apprehension seen in stimulant withdrawal (Graddy & Rastegar, 2020) parallel symptoms of primary anxiety disorders, which also involve dysfunction in limbic and stress-related circuits (Munir & Takov, 2021; Hale, 1997).

**The Prefrontal Cortex and Executive Function:** The prefrontal cortex (PFC) is responsible for executive functions, including impulse control, decision-making, and regulating emotional responses (Lahey, 2021). Chronic stimulant use is associated with functional and possibly structural deficits in the PFC, particularly in areas like the orbitofrontal and anterior cingulate cortex (Guardia Serecigni et al., 2001; Majewska, 1996). This impairment in executive function contributes to the loss of control over drug-seeking and the compulsive nature of addiction (Koob, 2020; Vanderschuren, 2008). During withdrawal, PFC dysfunction manifests as difficulty concentrating, indecisiveness, and poor impulse control, all of which are common clinical features (Graddy & Rastegar, 2020; Sheets & Brosse, 2010). These cognitive deficits overlap with those seen in major depression, where hypofrontality is a consistent neuroimaging finding (Peretti et al., 2009; Ruiz‐Rizzo & Lópera Restrepo, 2008). The inability to regulate the powerful, bottom-up drive for the drug emanating from sensitized limbic circuits is a core feature of the addicted state, exacerbated during the distress of withdrawal (Koob, 2020).

## Genetic and Molecular Basis

The transition from voluntary drug use to compulsive use and the severity of the subsequent withdrawal syndrome are influenced by a complex interplay of genetic predispositions and drug-induced molecular changes. Individual vulnerability to developing a stimulant use disorder is not uniform, suggesting a significant role for heritable factors (Blum & Trachtenberg, 1988; Pickard, 2011).

### Genetic Factors and Heritability

Family, twin, and adoption studies have consistently shown that substance use disorders, including those involving stimulants, have a substantial genetic component (Blum & Trachtenberg, 1988; Yarlagadda et al., 2007). This genetic vulnerability is not for addiction to a specific substance but rather a general predisposition to addictive behaviors (Sussman, 2025). This predisposition may be mediated by inherited differences in the neurobiology of reward, stress sensitivity, and impulse control (Pickard, 2011).

Candidate gene studies have focused on components of the monoamine systems, given their central role in stimulant pharmacology. Polymorphisms in genes encoding for dopamine receptors (e.g., the DRD2 gene), the dopamine transporter (DAT), and enzymes involved in dopamine metabolism (e.g., MAO-B) have been investigated as potential risk factors (Tudor et al., 2017; Kumar et al., 2019). For instance, certain variants of the DRD2 gene have been associated with reduced D2 receptor density, which could theoretically predispose individuals to seek drugs that enhance dopamine signaling (Yui et al., 2006). Similarly, genetic variations influencing serotonin and norepinephrine systems may contribute to individual differences in mood and anxiety responses to both stimulant use and withdrawal (Homberg & Contet, 2009). The high comorbidity between substance use disorders and other psychiatric conditions like bipolar disorder and schizophrenia suggests a shared genetic diathesis (Bućan, 2016; Keith, 2007).

### Molecular and Epigenetic Mechanisms

Chronic stimulant use induces lasting changes in gene expression within critical brain circuits, a process central to the concept of addiction as a form of drug-induced neural plasticity (Kalivas et al., 2003; Parolaro et al., 2005). These changes are mediated by transcription factors, such as cAMP response element-binding protein (CREB) and ΔFosB (Antonio & Alfredo, 2012). CREB activation is associated with the negative emotional state of withdrawal, while the accumulation of the highly stable protein ΔFosB is linked to the long-term process of sensitization and increased vulnerability to relapse (Kalivas et al., 2003; Antonio & Alfredo, 2012). These transcription factors alter the expression of numerous downstream genes, leading to structural and functional changes at the synaptic level (Kalivas et al., 2003).

Epigenetic modifications, which are heritable changes in gene function that do not involve alterations to the DNA sequence itself, are increasingly recognized as a key mechanism by which environmental factors like drug exposure and stress can produce long-lasting changes in brain function and behavior (Coelho et al., 2023). Mechanisms such as DNA methylation and histone modification can alter the accessibility of genes to transcription factors, thereby regulating their expression (Coelho et al., 2023). Chronic stimulant use has been shown to induce such epigenetic changes in reward-related brain regions, potentially "locking in" the altered patterns of gene expression that underlie the addicted state and withdrawal phenomena (Sussman, 2025; Coelho et al., 2023). Stress, a major factor in both the development of addiction and relapse, also exerts its long-term effects on the brain via epigenetic mechanisms, highlighting a convergence of pathways that contribute to vulnerability (Wand, 2008; Coelho et al., 2023).

## Brain Structure and Function

Neuroimaging studies in individuals with stimulant use disorders have revealed alterations in both brain structure and function that are believed to contribute to the symptoms of withdrawal and the chronic nature of the disorder. While direct imaging of the withdrawal state itself is less common, findings from studies of chronic users and abstinent individuals provide crucial insights into the enduring neural consequences of stimulant use.

### Structural Neuroimaging Findings

Structural magnetic resonance imaging (MRI) studies have identified volumetric changes in several brain regions in chronic stimulant users. Reductions in gray matter volume have been reported in prefrontal cortical areas, including the orbitofrontal cortex and anterior cingulate cortex, as well as in limbic structures like the insula and temporal lobe (Guardia Serecigni et al., 2001; Majewska, 1996). These structural deficits are consistent with the functional impairments in executive control, impulse regulation, and emotional processing commonly seen in addiction (Koob, 2020). The observation of ventricular enlargement in some studies suggests generalized brain atrophy, potentially resulting from the neurotoxic effects of stimulants or associated lifestyle factors (Volkow & Wolf, 1991; Majewska, 1996). Such atrophic changes have also been noted in other conditions involving cognitive decline, such as alcoholism and dementia (Page, 1983; Presečki et al., 2014). The degree to which these structural changes are reversible with prolonged abstinence is a key area of ongoing research, but they likely contribute to the persistent cognitive and behavioral deficits that complicate recovery.

### Functional Neuroimaging Findings

Functional neuroimaging techniques, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), have provided direct evidence of neurotransmitter system dysregulation in stimulant withdrawal. The most consistent finding from PET studies is a reduction in dopamine D2 receptor availability in the striatum of detoxified cocaine and methamphetamine users (Heinz, 2002; Volkow & Wolf, 1991). This reduction in D2 receptors correlates with impaired frontal lobe metabolism and is associated with the severity of craving and anhedonia, supporting the hypo-dopaminergic model of withdrawal (Heinz, 2002).

Functional MRI (fMRI) studies have examined brain activation patterns in response to drug-related cues and during cognitive tasks. During abstinence, stimulant users show heightened activation in reward and memory circuits—including the amygdala, hippocampus, and prefrontal cortex—when presented with cues associated with their drug use (Beninger, 2018; Daley & Douaihy, 2019). This neural reactivity to cues is thought to be the substrate of craving and is a powerful driver of relapse (Stewart, 2003). Conversely, during tasks that require executive control, abstinent users often show hypoactivation in prefrontal regions, reflecting the executive dysfunction that characterizes addiction (Guardia Serecigni et al., 2001; Koob, 2020). The pattern of limbic hyper-reactivity and prefrontal hypo-reactivity is a central theme in the neurobiology of addiction, representing a brain state biased toward impulsive, drug-seeking behavior and away from reflective, goal-directed control (Koob, 2020). These functional alterations are not static and can be modulated by factors like stress, which is known to impact brain function and cognition (Sandi, 2013).

## Developmental Neurobiology

The impact of stimulant use and the nature of the subsequent withdrawal syndrome are significantly influenced by the developmental stage at which exposure occurs. Adolescence, in particular, is a critical period of brain development, characterized by ongoing maturation of key neural circuits, which renders the brain uniquely vulnerable to the effects of drugs of abuse (Winters & Ingwalson, 2022; Groisman & Seminatore, 2003).

### Adolescent Vulnerability

The adolescent brain undergoes significant remodeling, especially in the prefrontal cortex and mesolimbic dopamine systems, which are central to decision-making, impulse control, and reward processing (Winters & Ingwalson, 2022; Lahey, 2021). During this period, there is a relative imbalance, with a hyper-responsive reward system and a still-developing prefrontal executive control system. This neurodevelopmental profile contributes to the characteristic risk-taking and novelty-seeking behaviors of adolescence, which can increase the likelihood of initiating substance use (Winters & Ingwalson, 2022; Flores, 2010).

Exposure to stimulants during this vulnerable window can disrupt normal neurodevelopmental trajectories (Groisman & Seminatore, 2003). Animal studies suggest that adolescent exposure to stimulants can lead to more profound and lasting changes in dopamine and glutamate systems compared to adult exposure (Majewska, 1996). This may result in a more severe addictive phenotype, heightened vulnerability to relapse, and more pronounced cognitive deficits in adulthood (Groisman & Seminatore, 2003; Winters & Ingwalson, 2022). The high comorbidity of ADHD in adolescence, a condition often treated with prescription stimulants, presents a complex clinical scenario where therapeutic use must be carefully distinguished from misuse and potential for a substance use disorder (Spencer et al., 2002; Mast et al., 2019).

The withdrawal syndrome in adolescents may also present differently. While the core features of dysphoria and fatigue are present, behavioral manifestations such as irritability, aggression, and mood lability can be more pronounced, overlapping with symptoms of other adolescent-onset psychiatric disorders like disruptive mood dysregulation disorder or bipolar disorder (Carlson & Pataki, 2016; MacPherson, 2019). The failure to achieve age-appropriate developmental milestones in social, academic, or interpersonal domains is a significant consequence of early-onset substance use and the subsequent cycles of intoxication and withdrawal (Groisman & Seminatore, 2003; Winters & Ingwalson, 2022).

### Critical Periods and Long-Term Consequences

The concept of critical periods in neurodevelopment suggests that exposure to drugs at specific times can have irreversible consequences. Stimulant use during adolescence may alter the "set point" of reward and stress systems, leading to a lifelong increased vulnerability to addiction and other psychiatric disorders (Wand, 2008). The cognitive impairments associated with adolescent stimulant use, particularly in executive functions like attention and working memory, can persist long after cessation of the drug, impacting academic and occupational achievement (Groisman & Seminatore, 2003; Dervaux, 2013). These long-term neuropsychological deficits are a significant and often underappreciated consequence of early drug exposure, contributing to the chronic disability associated with addiction (Page, 1983). Furthermore, early life stress and trauma are potent risk factors for the development of substance use disorders, likely by sensitizing stress and reward circuits in the brain, making them more susceptible to the effects of drugs later in life (Homberg & Contet, 2009; Wand, 2008).

## Treatment Mechanisms

The management of stimulant withdrawal is primarily supportive, focusing on alleviating symptoms and preventing relapse (Graddy & Rastegar, 2020). While no medications are consistently effective or FDA-approved specifically for this indication, various pharmacological strategies target the underlying neurobiological disturbances (Graddy & Rastegar, 2025; Thompson & Weber, 2021).

### Pharmacological Interventions

The primary goal of pharmacotherapy during stimulant withdrawal is to normalize the dysregulated neurotransmitter systems. Given the profound depressive symptoms and anhedonia, which are thought to stem from a hypo-dopaminergic and hypo-serotonergic state, antidepressant medications are frequently considered (Hall et al., 1990).

**Dopaminergic and Noradrenergic Agents:** Medications that modulate dopamine and norepinephrine systems, such as bupropion, have shown some promise (Graddy & Rastegar, 2025). Bupropion, a norepinephrine-dopamine reuptake inhibitor, may help alleviate the fatigue, anhedonia, and craving associated with withdrawal by partially correcting the monoamine deficit (Clayton, 2007; Hall et al., 1990). The use of prescription stimulants themselves (e.g., long-acting amphetamines) as a form of substitution therapy has been explored, with the rationale being to stabilize the dopamine system and reduce illicit use, although evidence for reducing complications is limited (Graddy & Rastegar, 2025; Rastegar & Fingerhood, 2015). Dopamine agonists like bromocriptine have also been studied to reduce withdrawal symptoms, but results have been inconsistent (Hall et al., 1990; Cocores et al., 1987).

**Serotonergic Agents:** Selective serotonin reuptake inhibitors (SSRIs) are often used to treat the depressive and anxiety symptoms of withdrawal (Graddy & Rastegar, 2025). By increasing synaptic serotonin, these agents may counteract the serotonergic deficits induced by chronic stimulant use, particularly with drugs like MDMA (Parrott, 2001). The efficacy of SSRIs in this context may be limited to patients with a clear depressive syndrome that persists beyond the acute withdrawal phase (McIntosh & Ritson, 2001).

**GABAergic and Glutamatergic Modulators:** Given the role of excitatory/inhibitory imbalance in withdrawal, medications targeting GABA and glutamate systems are of interest. Anticonvulsants like topiramate, which enhances GABA function and antagonizes glutamate receptors, have shown some promise in reducing stimulant use (Graddy & Rastegar, 2025; Johnson et al., 2007). Baclofen, a GABA-B agonist, has also been studied for its potential to reduce craving and use (Rolland et al., 2018). These agents may work by reducing the neuronal hyperexcitability that contributes to anxiety, irritability, and craving during withdrawal (Söderpalm, 2002).

**Sleep Aids:** Insomnia is a common and distressing symptom of stimulant withdrawal (Graddy & Rastegar, 2020). While benzodiazepines can be effective, their use is often discouraged due to their own potential for dependence and abuse (Thompson & Weber, 2021; Nelson & Chouinard, 1999). Non-benzodiazepine hypnotics (e.g., zolpidem) or sedating antidepressants like mirtazapine or trazodone are often preferred to help restore a normal sleep-wake cycle (Bogan, 2008; Baandrup et al., 2012; Graddy & Rastegar, 2025). Restoring sleep is critical, as sleep deprivation itself can exacerbate mood disturbances, cognitive impairment, and craving (Bjorvatn et al., 2021; Lanièpce et al., 2020).

### Neuroplasticity and Non-Pharmacological Approaches

Ultimately, recovery from stimulant addiction and withdrawal involves the reversal of drug-induced neuroplastic changes and the re-establishment of healthy behavioral patterns (Kalivas et al., 2003). Psychosocial interventions, such as cognitive-behavioral therapy (CBT) and contingency management, are mainstays of treatment (Graddy & Rastegar, 2020). From a neurobiological perspective, these therapies work by strengthening prefrontal cortical control over impulsive, subcortical drives for the drug (Koob, 2020). CBT helps individuals identify and change maladaptive thought patterns and behaviors related to drug use, effectively helping to "rewire" the brain's response to cues and stressors (Arch & Craske, 2009).

Emerging evidence also supports the role of physical exercise as an adjunct treatment. Exercise has been shown to have antidepressant and anxiolytic effects, potentially by modulating monoamine systems, increasing neurotrophic factors like BDNF, and regulating the HPA axis stress response (Cooney, 2013; Sarris et al., 2014; Chaouloff et al., 2013). By providing a natural source of reward and promoting neuroplasticity, exercise may help counteract the anhedonia and cognitive deficits of withdrawal and reduce relapse vulnerability (Meeusen et al., 2020).

## Future Directions

While our understanding of the neurobiology of stimulant withdrawal has advanced significantly, numerous questions remain, and several emerging research areas hold promise for improving diagnosis and treatment. The current knowledge base is limited, often relying on extrapolations from related conditions due to a scarcity of direct, hypothesis-driven research in humans experiencing stimulant withdrawal (Thompson & Weber, 2021).

One critical area for future research is the development of reliable biomarkers to objectively quantify the severity of withdrawal and predict clinical outcomes. Neuroimaging techniques, such as fMRI and PET, could be used longitudinally to track changes in functional connectivity, receptor density, and neuroinflammation during abstinence, potentially identifying neural signatures that predict relapse (Dell’Osso et al., 2012). Similarly, peripheral markers, such as inflammatory cytokines or stress hormones, may reflect central nervous system states and offer a more accessible means of monitoring the withdrawal process (Anisman et al., 2005; Anisman & Merali, 2003). The link between inflammatory processes and depression is well-established, suggesting that neuroinflammation may be a key component of the withdrawal-induced negative affective state (Anisman et al., 2005).

The development of novel pharmacotherapies remains a high priority. Current approaches are largely repurposed from treatments for other psychiatric disorders and have shown limited and inconsistent efficacy (Graddy & Rastegar, 2025). Future drug development could target more specific mechanisms implicated in withdrawal. For example, agents that selectively modulate glutamatergic plasticity, such as NMDA receptor antagonists or mGluR modulators, could potentially reverse the maladaptive circuit changes that drive craving and relapse (Zhang & Hashimoto, 2018; Kalivas et al., 2003). Similarly, targeting the brain's stress systems, for instance with CRF antagonists, represents a promising strategy to alleviate the negative emotional state of withdrawal that is a powerful motivator for continued drug use (Koob, 2020; Vendruscolo & Koob, 2019). The endocannabinoid system, which modulates stress and reward, is another emerging target (Parolaro et al., 2005; Coelho et al., 2023).

Further research is also needed to understand the heterogeneity of the withdrawal experience. Not all individuals who stop using stimulants experience the same symptoms or severity, suggesting the influence of factors like genetics, sex, age of onset, pattern of use, and psychiatric comorbidity (Pickard, 2011; Winters & Ingwalson, 2022). Identifying biological subtypes of stimulant withdrawal could pave the way for personalized medicine, where treatments are tailored to an individual's specific neurobiological profile (Werner & Coveñas, 2016). For example, individuals with a particular genetic polymorphism affecting dopamine function might respond better to a dopaminergic agent, whereas those with marked HPA axis dysregulation might benefit more from a stress-system modulator (Yui et al., 2006; Wand, 2008).

Finally, the long-term neurobiological consequences of stimulant withdrawal, including the potential for persistent cognitive deficits and structural brain changes, require more extensive investigation. Longitudinal studies are needed to determine the extent and time course of neural recovery with sustained abstinence and to identify interventions, such as cognitive remediation or exercise, that might accelerate this process (Page, 1983; Behrman & Ebmeier, 2014). Understanding the mechanisms of both damage and repair is crucial for developing strategies to mitigate the lasting impact of stimulant use disorder on brain health and function.

## Conclusion

Stimulant withdrawal is a complex neuropsychiatric syndrome driven by profound neuroadaptations in brain systems that regulate reward, motivation, stress, and executive function. The cessation of chronic stimulant use unmasks a state of neurochemical imbalance, centrally characterized by a hypofunction of the mesolimbic dopamine system and hyperactivity of brain stress systems, such as the extended amygdala (Koob, 2020; Heinz, 2002). This allostatic state manifests clinically as a distressing constellation of symptoms including dysphoria, anhedonia, fatigue, anxiety, and severe sleep disruption, which collectively create a powerful negative reinforcement signal that promotes relapse (Graddy & Rastegar, 2025; Thompson & Weber, 2021).

The biological mechanisms are multifaceted, involving dysregulation not only of dopamine but also of serotonin, norepinephrine, glutamate, and GABA systems (Antonio & Alfredo, 2012; Eşel, 2006). These neurotransmitter disturbances occur across a network of interconnected brain regions, including the nucleus accumbens, prefrontal cortex, and amygdala, leading to altered functional connectivity and impaired top-down cognitive control over drug-seeking urges (Kalivas et al., 2003; Koob, 2020). At a molecular level, drug-induced changes in gene expression, mediated by transcription factors and epigenetic modifications, create a lasting "molecular scar" that contributes to the chronicity of addiction and the persistent vulnerability to relapse (Kalivas et al., 2003; Coelho et al., 2023).

While the symptomatic overlap with primary mood and anxiety disorders provides a framework for understanding the affective components of withdrawal, it is crucial to recognize that stimulant withdrawal is a distinct clinical entity rooted in the pharmacology of the abused substance (Daley & Douaihy, 2019). The current lack of specifically approved and consistently effective pharmacotherapies highlights the significant unmet need in this area (Graddy & Rastegar, 2025). Future research must focus on elucidating the heterogeneity of the withdrawal syndrome, identifying predictive biomarkers, and developing novel therapeutic agents that target the core neurobiological drivers of withdrawal-induced negative affect and craving. A comprehensive approach that integrates supportive care with targeted biological and psychosocial interventions offers the best prospect for helping individuals navigate the challenges of withdrawal and achieve sustained recovery.


## References

1. Abe, Y., & Germai, A. (2012). Insomnia and Its Correlates: Current Concepts, Epidemiology, Pathophysiology and Future Remarks. InTech eBooks. https://doi.org/10.5772/36102
2. Abhilash, K. P., Jha, A., Bandhyopadhyay, R., & Victor, P. (2014). Hypoglycemia - A rare complication of carbamazepine overdose. Indian Journal of Pharmacology. https://doi.org/10.4103/0253-7613.144941
3. Adams, C. E., Wilson, P., Gilbody, S., Bagnall, A., & Lewis, R. (2000). Drug treatments for schizophrenia. Quality in Health Care. https://doi.org/10.1136/qhc.9.1.73
4. Adell, A., & Salas, M. G. (2018). The ampakine CX717 has a rapid, but short-lasting antidepressant-like activity in the rat. https://doi.org/10.26226/morressier.5b681761b56e9b005965c72d
5. Agarwal, V., Sitholey, P., & Srivastava, C. (2019). Clinical practice guidelines for the management of dissociative disorders in children and adolescents. Indian Journal of Psychiatry. https://doi.org/10.4103/psychiatry.indianjpsychiatry_493_18
6. Aguiar, I. G., Gomes, S., Moreira, A. M., Henriques, V., & Silva, H. (2012). P-01 - Cafeinism and psychosis - when the habit becomes a threat. European Psychiatry. https://doi.org/10.1016/s0924-9338(12)74168-8
7. Ahemad, M., Ahmad, P. M. F., & Shafaat, M. (2018). Effect of Dalak (Massage) in the Management of Sahar (Insomnia). https://doi.org/10.37591/rrjoush.v5i2.130
8. Ahlskog, J. E., & Wilkinson, J. M. (1990). New concepts in the treatment of Parkinson's disease.. PubMed.
9. Ainsworth, P. (1998). Attention deficit hyperactivity disorder: diagnostic issues. Morecambe Bay medical journal. https://doi.org/10.48037/mbmj.v3i2.541
10. Alfarossi, O. L., & Hutasoit, H. B. K. (2020). Gejala Psikotik pada Pasien dengan Epilepsi Tidak Terkontrol. Jurnal Medula.
11. Ali, N., Rasheed, A., Tariq, I., Abdullah, F., Sarwar, A., Atta, R., & Qammer, Z. (2018). Adjunct Use of Low Dose Risperidone Verses Adjunct Use of Clonazepam with an SSRI in Treatment of Moderate to Severe Anxiety States; A Comparative Study. National Journal of Health Sciences. https://doi.org/10.21089/njhs.32.0051
12. Alqallaf, M. (2021). Toxicological Aspect of Fatal Methamphetamine. Chemical & Pharmaceutical Research. https://doi.org/10.33425/2689-1050.1016
13. Altınbaş, K., Can, A. A., Kurt, E., & Uygur, N. (2014). Delirious mania: Clinical course and treatment. Journal of Mood Disorders. https://doi.org/10.5455/jmood.20140901035042
14. Amann, B. L., Erfurth, A., & Grunze, H. (1999). Treatment of tardive akathisia with clonidine: a case report. The International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145799001376
15. Ameli, P., Robinson, C. P., & Hocker, S. E. (2025). Status Epilepticus. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197628638.003.0098
16. Amihăesei, I. C., & Cojocaru, E. (2014). Main neuroendocrine features, diagnosis and therapeutic possibilities in the chronic fatigue syndrome, an underdiagnosed entity.. PubMed.
17. Amihăesei, I. C., & Mungiu, O. C. (2013). Main neuroendocrine features and therapy in primary sleep troubles.. PubMed.
18. Amorim, M. J., Maurício, J., & Brandão, D. (2019). WHEN THE DISEASE ARISES FROM THE TREATMENT: CORTICOSTEROID-INDUCED PSYCHOSIS A CASE REPORT AND BRIEF LITERATURE REVIEW. https://doi.org/10.26226/morressier.5d1a037b57558b317a140b63
19. Anari, A., Ghaffarinejad, A., & Sabzevari, L. (2012). P-66 - The prolonged syndrome of opium withdrawal. European Psychiatry. https://doi.org/10.1016/s0924-9338(12)74233-5
20. Andrés, P., Ortega, T., López‐Sobaler, A. M., Ortega, A., Redondo, R. A., Jímenez, A. I., & Chacón, L. (1994). [The role of folates in the diverse biochemical processes that control mental function].. PubMed.
21. Anghel, L., Boev, M., Stănescu, C., Caramfil, S. M., Luca, L., Mușat, C. L., & Ciubară, A. (2023). Depression in the Diabetic Patient. BRAIN BROAD RESEARCH IN ARTIFICIAL INTELLIGENCE AND NEUROSCIENCE. https://doi.org/10.18662/brain/14.4/526
22. Anghelescu, G., Bojescu, A. A., Populeanu, R., Ionică, M., Vlădescu, M., Macovei, R. A., & Caragea, G. (2018). Multiple reactions monitoring for cocaine and ethylbenzoylecgonine to increase the signal/noise ratio in mass spectrometry analysis. Advanced Topics in Optoelectronics, Microelectronics, and Nanotechnologies IX. https://doi.org/10.1117/12.2322569
23. Anisman, H., & Merali, Z. (1999). Understanding stress: characteristics and caveats.. PubMed.
24. Anisman, H., & Merali, Z. (2003). Cytokines, stress and depressive illness: brain‐immune interactions. Annals of Medicine. https://doi.org/10.1080/07853890310004075
25. Anisman, H., Merali, Z., Poulter, M. O., & Hayley, S. (2005). Cytokines as a Precipitant of Depressive Illness: Animal and Human Studies. Current Pharmaceutical Design. https://doi.org/10.2174/1381612053381701
26. Antonaci, F., Sances, G., Manni, R., & Buzzi, M. G. (1996). Epileptic seizure during aspirin and caffeine withdrawal in a drug induced headache.. PubMed.
27. Antonio, E., & Alfredo, E. (2012). Cocaine Addiction: Changes in Excitatory and Inhibitory Neurotransmission. InTech eBooks. https://doi.org/10.5772/34410
28. Anuzyte, J. S., Rutkauskaitė, G., & Mameniškienė, R. (2018). Transient epileptic amnesia. Neurologijos seminarai. https://doi.org/10.29014/ns.2018.26
29. Apovian, C. M., & Ness-Abramof, R. (2005). Drug-induced weight gain. Drugs of today. https://doi.org/10.1358/dot.2005.41.8.893630
30. Aptikieva, L. (2020). PSYCHOLOGICAL VIOLENCE CONSEQUENCES FOR DIFFERENT AGE CATEGORIES. Vestnik Orenburgskogo gosudarstvennogo universiteta. https://doi.org/10.25198/1814-6457-224-6
31. Arendt, M., Rosenberg, R., Fjordback, L., Brandholdt, J., Foldager, L., Sher, L., & Munk-Jørgensen, P. (2007). Testing the self-medication hypothesis of depression and aggression in cannabis dependent subjects. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2007.01.601
32. Arenson, C., Busby‐Whitehead, J., Brummel‐Smith, K., O’Brien, J. G., Palmer, M. H., & Reichel, W. (2010). Evaluation and Management of Dementia. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511575952.017
33. Arredondo-Aldana, K., Mera-Posligua, M. J., & Alencastro, J. A. P. (2021). Trastorno Depresivo Persistente y Trastornos de Ansiedad Generalizada Proveniente de un Estrés Post Traumático Crónico: Presentación de un Caso Clínico. Revista Científica Arbitrada en Investigaciones de la Salud GESTAR. https://doi.org/10.46296/gt.v4i8edesp.0027
34. Arteaga, T. L., Amo, C., González, C. S., & Sánchez, D. H. (2016). Nonconvulsive status epilepticus and psychotic symptoms: case report Stato epilettico non convulsivo e sintomi psicotici: caso clinico.
35. Autor, S. (2002). CÁPSULAS PARA LA VIDA.- ANSIEDAD. Gaceta UNAM (2000-2009).
36. Avari, J., Yuen, G. S., AbdelMalak, B., Mahgoub, N., Kalayam, B., & Alexopoulos, G. S. (2014). Assessment and Management of Late-Life Depression. Psychiatric Annals. https://doi.org/10.3928/00485713-20140306-04
37. Awan, K., & Steinberg, M. H. (2017). Medical Conditions That May Cause Cognitive Impairment and Depression. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199959549.003.0005
38. b'Volkow, N. D., & b'Wolf, A. P. (1991). b'THE USE OF POSITRON EMISSION TOMOGRAPHY IN IDENTIFYING AND QUANTIFYING RECEPTORS INVOLVED IN SCHIZOPHRENIA.'.
39. Baandrup, L., Jennum, P., Lublin, H., & Glenthøj, B. (2012). Treatment options for residual insomnia in schizophrenia. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/acps.12016
40. Bachmann, M., & Röhr, H.-P. (1983). A Speculative Illness Model of Over-Eating and Anorexia Nervosa. Psychological Reports. https://doi.org/10.2466/pr0.1983.53.3.831
41. Bains, N., Abdijadid, S., & Miller, J. (2021). Major Depressive Disorder (Nursing).
42. Baldessarini, R. J. (1989). Current status of antidepressants: clinical pharmacology and therapy.. PubMed.
43. Baldwin, D. S., Ajel, K., & Garner, M. (2008). Anxiety disorders. Medicine. https://doi.org/10.1016/j.mpmed.2008.05.002
44. Balis, G. U. (2018). Syndromes Similar to Functional Disorders. Routledge eBooks. https://doi.org/10.4324/9781315825908-13
45. Balis, G. U. (2018). Withdrawal and Intoxication. Routledge eBooks. https://doi.org/10.4324/9781315825908-14
46. Balvir, K. S., Dhanvij, B., Telrandhe, S., & Wajgi, R. D. (2021). A Case Report on Management of Subdural Hematoma. NVEO - NATURAL VOLATILES & ESSENTIAL OILS Journal | NVEO.
47. Bannon, M. J., Bannon, E. E., & Bannon, K. T. (2020). Dopamine. Encyclopedia of Life Sciences. https://doi.org/10.1002/9780470015902.a0000279.pub4
48. Basu, D., Sharma, A., & Nebhinani, N. (2009). Disulfiram-induced delirium: diagnostic dilemma.
49. Batinić, B., Duišin, D., & Vukosavljevic-Gvozden, T. (2017). Neurobiological bases for impulsive and compulsive behaviour: Implications for pharmacological and psychological interventions. Engrami. https://doi.org/10.5937/engrami1701017b
50. Battaglia, J., Robinson, D. G., & Citrome, L. (2007). The Treatment of Acute Agitation in Schizophrenia. CNS Spectrums. https://doi.org/10.1017/s1092852900026146
51. Baumann, P., & Martin-Du, P. R. (2008). Sexual dysfunctions induced by antidepressants and antipsychotics.
52. Becker, H. C., & Redmond, N. (2002). Role of Glutamate in Alcohol Withdrawal Kindling. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-306-4_25
53. Becker, S. P., & Barkley, R. A. (2018). Sluggish cognitive tempo. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198739258.003.0015
54. Beghi, E., Carpio, A., Forsgren, L., Hesdorffer, D. C., Malmgren, K., Sander, J. W., Tomson, T., & Hauser, W. A. (2009). Recommendation for a definition of acute symptomatic seizure. Epilepsia. https://doi.org/10.1111/j.1528-1167.2009.02285.x
55. Behrman, S., & Ebmeier, K. P. (2014). Can exercise prevent cognitive decline?. PubMed.
56. Bell, B. (2008). Depression and Parkinson’s Disease. touchREVIEWS in Neurology. https://doi.org/10.17925/usn.2008.04.01.67
57. Bell, C. M. (2009). L. https://doi.org/10.1093/oso/9780195341591.003.0012
58. Bell, D. S. (1973). The Experimental Reproduction of Amphetamine Psychosis. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1973.04200010020003
59. Bellamkonda, P., Mansou, G., Tantoush, H., & Abuzaid, A. (2014). Marijuana Induced Transient Global Amnesia.
60. Benarroch, E. E. (2014). Autonomic Hyperactivity. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199920198.003.0013
61. Beninger, R. J. (2018). Life's rewards. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198824091.001.0001
62. Bertodo, T. D. S., Gross, M. S., & Maldaner, E. B. (2018). TRANSTORNOS BIPOLAR E DEPRESSIVO: UMA REVISÃO DOS ASPECTOS CONCEITUAIS.
63. Bjorvatn, B., Jernelöv, S., & Pallesen, S. (2021). Insomnia – A Heterogenic Disorder Often Comorbid With Psychological and Somatic Disorders and Diseases: A Narrative Review With Focus on Diagnostic and Treatment Challenges. Frontiers in Psychology. https://doi.org/10.3389/fpsyg.2021.639198
64. Blanc, F., & Verny, M. (2017). Prodromal stage of disease (dementia) with Lewy bodies, how to diagnose in practice?. Gériatrie et Psychologie Neuropsychiatrie du Viellissement. https://doi.org/10.1684/pnv.2017.0675
65. Blanco, C., & Bernardi, S. (2014). Gambling Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg62
66. Blum, K., & Trachtenberg, M. C. (1988). Alcoholism: Scientific Basis of a Neuropsychogenetic Disease. International Journal of the Addictions. https://doi.org/10.3109/10826088809058839
67. Bogan, R. (2008). Treatment Options for Insomnia-Pharmacodynamics of Zolpidem Extended-Release to Benefit Next-Day Performance. Postgraduate Medicine. https://doi.org/10.3810/pgm.2008.09.1916
68. Boggs, C. L., Ripple, M., Ali, Z., Brassell, M., Levine, B., Jufer‐Phipps, R., Doyon, S., & Fowler, D. R. (2013). Anaphylaxis After the Injection of Buprenorphine. Journal of Forensic Sciences. https://doi.org/10.1111/1556-4029.12161
69. Bokor, G., & Anderson, P. (2014). Ketamine. Journal of Pharmacy Practice. https://doi.org/10.1177/0897190014525754
70. Bonnet, M. H., & Arand, D. L. (2013). Insomnia. https://doi.org/10.3920/9789086867639_003
71. Bourin, M., David, D. J., & Dhonnchadha, B. À. N. (2002). Sedation: a non-specific phenomenon -. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology.
72. Boylan, K., & Eppel, A. (2008). The severe mood dysregulation phenotype: case description of a female adolescent.. PubMed.
73. Bradic, L., Lokmić-Pekić, I., & Dzevad, B. (2018). Psychiatric comorbidity in patients with posttraumatic stress disorder and enduring personality change after catastrophic experience. https://doi.org/10.26226/morressier.5b68175cb56e9b005965c22b
74. Bragazzi, N. L., Khabbache, H., Perduca, M., Neri, B., Firenzuoli, F., Penazzi, G., Simíμes, M., Zerbetto, R., & Re, T. S. (2018). Parapsychology, N,N-Dimethyltryptamine and the Pineal Gland. Cosmos and history.
75. Brandish, E. K., & Baldwin, D. S. (2012). Anxiety disorders. Medicine. https://doi.org/10.1016/j.mpmed.2012.08.017
76. Brody, D. L. (2019). How Do You Make the Diagnosis of Concussion?. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190054793.003.0003
77. Brola, W., Ziomek, M., & Czernicki, J. (2007). [Fatigue syndrome in chronic neurological disorders].. PubMed.
78. Brouwer, A., Carhart‐Harris, R., & Raison, C. L. (2023). Psychotomimetic Compensation and Sensitization. https://doi.org/10.31234/osf.io/y8dn2
79. Brückner, K. (2020). Cognitive and Psychological Side Effects of Antiepileptic Drugs. IntechOpen eBooks. https://doi.org/10.5772/intechopen.94308
80. Brüne, M., & Kahlert, I. (2001). Über einen Fall von primärer Zopiclonabhängigkeit. DMW - Deutsche Medizinische Wochenschrift. https://doi.org/10.1055/s-2001-14488
81. BS, A. H., & BA, M. F. (2018). Glossary. https://doi.org/10.1002/9781119449737.gloss
82. BSc, P. L. G. R., & BSc, D. B. R. (2008). Glossary of Technical Terms. https://doi.org/10.1002/9781444302264.gloss
83. Buckley, P., & Foster, A. (2014). Schizophrenia. https://doi.org/10.1007/978-3-7091-0715-7_4
84. Budson, A. E., & O’Connor, M. K. (2021). How to manage emotional problems. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780190098124.003.0008
85. Budson, A. E., & O’Connor, M. K. (2021). Which medications can improve thinking, memory, behavior, or function?. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780190098124.003.0013
86. Bueno, B. B., Soares, V. S., & Oliveira, C. F. D. (2014). Patologias associadas à deficiências na síntese do grupo heme. Revista Científica da FHO|Uniararas. https://doi.org/10.55660/revfho.v2i2.101
87. Bujosa, C. M., & Monsalve, M. H. (2007). Caso Clínico "La esquizofrenia de inicio senil o cuando el reto de saber pseudodiagnosticar". Norte de Salud mental.
88. Bundies, G. L., & Tyagi, H. (2021). #3095 Rapid anti-obsessive treatments of obsessive-compulsive disorder: reviewing effects of ketamine in OCD. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2021-bnpa.24
89. Burk, A., Merchant, A., Rahman, H., Patel, A., Deshmukh, I., Merchant, R., Yam, A. A., Yu, A., Cai, C., Hassam, A., Le, D., & Lambroussis, C. G. (2025). Serotonin Syndrome Without Overdose: Polypharmacy-Induced Toxicity in a Medically Stable Young Adult. Cureus. https://doi.org/10.7759/cureus.86587
90. Burkart, J., Jong, M. C., Ilenkyo, L., Verwer, C., Weber, S., Keller, T., & Klement, P. (2017). P172 Results of a randomised controlled trial with a homeopathic complex medicinal product in children with sleep disorders and restlessness. https://doi.org/10.1136/archdischild-2017-313273.260
91. Burke, A., Yaari, R., Tariot, P. N., Dougherty, J., Fleisher, A., & Brand, H. (2012). The Shadow People. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.12alz01398
92. Burkojus, D., Gelžinienė, G., Pajėdienė, E., Stankevičienė, G., Misevičienė, V., & Jurkevičienė, G. (2025). Factors Affecting Sleep and Wakefulness in People with Epilepsy: A Narrative Review. Medicina. https://doi.org/10.3390/medicina61061000
93. Bürk, K., Strelczyk, A., & Oertel, W. H. (2012). Intermittent Tunnel Vision in a Patient With Multiple Drug Abuse History. Movement Disorders. https://doi.org/10.1891/9781617050589.0090
94. Calingasan, N. Y., Sheu, K. R., Baker, H., Gandy, S., & Gibson, G. E. (1996). Thiamine Deficiency as a Model of Selective Neurodegeneration with Chronic Oxidative Deficits. Neurodegenerative Diseases. https://doi.org/10.1007/978-1-4899-0209-2_25
95. Canapathy, M., Kurushev, J., Chitra, F., & Dash, M. (2019). Impact of Sensory Deprivation on Health Outcome. Acta Scientific Paediatrics. https://doi.org/10.31080/aspe.2019.02.0165
96. Cangi, F., Boccuni, M., Fusco, B. M., Curradi, C., & Sicuteri, F. (1987). Pentazocine in Migraine: Subjective and Pupillary Abnormal Effects. Headache The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.1987.hed2709503.x
97. Capitani, E. M. D. (2009). Diagnóstico e tratamento da intoxicação por chumbo em crianças e adultos. Medicina (Ribeirão Preto). https://doi.org/10.11606/issn.2176-7262.v42i3p319-329
98. Carla, P., Liliana, P., & Castro, M. M. C. A. (2012). Li+ in Bipolar Disorder – Possible Mechanisms of Its Pharmacological Mode of Action. InTech eBooks. https://doi.org/10.5772/34560
99. Carlson, G. A., & Pataki, C. (2016). Disruptive Mood Dysregulation Disorder Among Children and Adolescents. FOCUS The Journal of Lifelong Learning in Psychiatry. https://doi.org/10.1176/appi.focus.20150039
100. Carrera, M. A. V., Correa, S. M. V., Prado, M. M. C., & Granados, K. P. M. (2019). Manejo de intoxicación por opioides. RECIMUNDO. https://doi.org/10.26820/recimundo/3.(4).diciembre.2019.494-510
101. Carvajal-Lohr, A., Flores‐Ramos, M., Montejo, S. I., & Vidal, C. G. (2016). Los trastornos de ansiedad durante la transición a la menopausia. Perinatología y Reproducción Humana. https://doi.org/10.1016/j.rprh.2016.03.003
102. CASEY, P., & Bailey, S. (2011). Adjustment disorders: the state of the art. World Psychiatry. https://doi.org/10.1002/j.2051-5545.2011.tb00003.x
103. Cash, E., Beck, I. T., & Davis, C. J. (2023). What factors influence individual differences in vulnerability/resilience to sleep loss and/or circadian misalignment?. Research Directions Sleep Psychology. https://doi.org/10.1017/slp.2023.6
104. Casper, R. C. (2018). Not the Function of Eating, but Spontaneous Activity and Energy Expenditure, Reflected in “Restlessness” and a “Drive for Activity” Appear to Be Dysregulated in Anorexia Nervosa: Treatment Implications. Frontiers in Psychology. https://doi.org/10.3389/fpsyg.2018.02303
105. Ceravolo, F., Sestito, S., Falvo, F., Salpietro, V., Polizzi, A., Ruggieri, M., Bruno, M., & Concolino, D. (2016). Neurological Involvement in Inherited Metabolic Diseases: An Overview. Journal of Pediatric Biochemistry. https://doi.org/10.1055/s-0036-1582235
106. Cha, Y., Baloh, R. W., Cho, C., Magnusson, M., Song, J., Strupp, M., Wuyts, F. L., & Staab, J. P. (2020). Mal de débarquement syndrome diagnostic criteria: Consensus document of the Classification Committee of the Bárány Society. Journal of Vestibular Research. https://doi.org/10.3233/ves-200714
107. Chandler, C. (2010). Glossary. https://doi.org/10.1002/9781444328172.gloss
108. Chang, Y.-S., Anderson, N., Long, K., Murphy, C., McMahan, V., Rodda, L. N., Kral, A. H., & Coffin, P. O. (2025). Refining cause of death attribution among opioid, opioid‐stimulant and stimulant acute toxicity deaths. Addiction. https://doi.org/10.1111/add.70190
109. Chaouloff, F., Dubreucq, S., Matias, I., & Marsicano, G. (2013). Physical activity feel-good effect:The role of endocannabinoids. Routledge eBooks. https://doi.org/10.4324/9780203132678-12
110. Chatterton, C., & Jones, G. (2013). Interpretative aspects of toxicological results. https://doi.org/10.4155/ebo.13.54
111. Chaudhry, H., Arshad, N., Niaz, S., Cheema, F., Iqbal, M., & Mufti, K. (2005). Fifteen-year follow-up of conversion disorder. International Psychiatry. https://doi.org/10.1192/s1749367600007517
112. Chaves, T. V. (2019). Through ketamine fields: pain and afterglow. https://doi.org/10.33612/diss.107955714
113. Chow, W., Khullar, A., Lalla, F., Lessard, S., Lowe, A., & McIntosh, D. (2025). Practical Recommendations for Hypnotic Switching in Insomnia Management: A Canadian Expert Clinical Framework. Canadian Primary Care Today. https://doi.org/10.58931/cpct.2025.3s0148
114. Chue, P., & Lalonde, J. (2014). Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s43404
115. Chummun, H., Tilley, V., & Ibe, J. (2010). 3,4-methylenedioxyamfetamine (ecstasy) use reduces cognition.. British Journal of Nursing.
116. Chung, S., Oh, K., Cho, K., & Hwang, I.-K. (2003). Antidepressant-Induced Somnambulism：A Case of Mirtazapine. Sleep Medicine and Psychophysiology.
117. Clarkson, P. M., & Miles, M. P. (1994). Exercise-induced muscle pain, soreness, and cramps.. PubMed.
118. Clay, S., Allen, J. V., & Parran, T. (2008). A Review of Addiction. Postgraduate Medicine. https://doi.org/10.3810/pgm.2008.07.1802
119. Clayton, A. H. (2007). Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity?. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.8.4.457
120. Cleeland, C. S., & Mendoza, T. R. (2010). Symptom measurement by patient report. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511780868.028
121. Cocores, J. A., Patel, M. D., Gold, M. S., & Pottash, A. C. (1987). Cocaine Abuse, Attention Deficit Disorder, and Bipolar Disorder. The Journal of Nervous and Mental Disease. https://doi.org/10.1097/00005053-198707000-00007
122. Coelho, A. A., Lima-Bastos, S., Gobira, P. H., & Lisboa, S. F. (2023). Endocannabinoid signaling and epigenetics modifications in the neurobiology of stress-related disorders. Neuronal Signaling. https://doi.org/10.1042/ns20220034
123. Colán, T. C., Gálvez, G. A., & Zevallos, D. C. (2013). Síntomas psiquiátricos e insulinoma: reporte de caso Psychiatric symptoms and insulinoma: a case report.
124. Conde, B. U. (2016). Trastorno de la conducta alimentaria, trastorno por déficit de atención e hiperactividad, e impulsividad: un estudio sobre su relación.
125. Connell, J., Oldham, M., Pandharipande, P. P., Dittus, R. S., Wilson, A. M., Mart, M. F., Heckers, S., Ely, E. W., & Wilson, J. E. (2022). Malignant Catatonia: A Review for the Intensivist. Journal of Intensive Care Medicine. https://doi.org/10.1177/08850666221114303
126. Connor, J. P., Stjepanović, D., Budney, A. J., Foll, B. L., & Hall, W. (2021). Clinical management of cannabis withdrawal. Addiction. https://doi.org/10.1111/add.15743
127. Consroe, P., & Snider, S. R. (2019). Therapeutic Potential of Cannabinoids in Neurological Disorders * , †. Chapman and Hall/CRC eBooks. https://doi.org/10.1201/9780429260667-2
128. Conti, P. C. R., Cunha, C. O., Conti, A. C. D. C. F., Bonjardim, L. R., Stuginski‐Barbosa, J., & Costa, Y. M. (2023). Secondary bruxism: A valid diagnosis or just a coincidental finding of additional masticatory muscle activity? A narrative review of literature. Journal of Oral Rehabilitation. https://doi.org/10.1111/joor.13592
129. Conway, K. P., Montoya, I. D., & Compton, W. M. (2007). Lifetime Psychiatric Comorbidity of Illicit Drug Use Disorders. The Psychiatric times.
130. Cooney, G. (2013). Exercise for depression. Journal of Evidence-Based Medicine. https://doi.org/10.1111/jebm.12076
131. Coronado, L. M. Q., Florez, D. A. C., & Tarazona, M. C. L. (2017). Prevalencia depresión en estudiantes universitarios Bucaramanga 2017.
132. Correll, C. U., Yu, X., Xiang, Y., Kane, J. M., & Masand, P. S. (2017). Biological treatment of Acute Agitation Or Aggression with Schizophrenia Or Bipolar Disorder in the Inpatient Setting. Annals of Clinical Psychiatry. https://doi.org/10.1177/104012371702900203
133. Costa, G. (2012). [Stress of driving: general overview].. PubMed.
134. Cottencin, O., Danel, T., Goudemand, M., Thomas, P., & Consoli, S. M. (2009). Catatonia recognition and treatment.. PubMed.
135. Couto, F. S. D., & Mendonça, A. D. (2010). Sintomas psiquiátricos e comportamentais da demência. Revista Portuguesa de Clínica Geral. https://doi.org/10.32385/rpmgf.v26i1.10713
136. Coutts, S. R., Smith, I., & Stirzaker, A. G. (2025). Clarithromycin-Induced Psychosis: When Is Delirium Not Delirium?. Cureus. https://doi.org/10.7759/cureus.93096
137. Cox, D. J., Burket, R. C., Mikami, A. Y., Moore, M., & Merkel, R. L. (2007). ADHD and the Adolescent Driver.
138. Cruickshank, C., & Dyer, K. R. (2009). A review of the clinical pharmacology of methamphetamine. Addiction. https://doi.org/10.1111/j.1360-0443.2009.02564.x
139. Cruz, M. C. D., Camargo, R. P. D., Cruz, L. C. D., Schiefelbein, N., Cruz, D. M. D., & Cruz, M. C. C. D. (2020). Migrânea: revisão de literatura. ARCHIVES OF HEALTH INVESTIGATION. https://doi.org/10.21270/archi.v10i2.4670
140. Cruz, S. L., & López, C. B. (2003). Fármacos que producen dependencia física y adicción. Avance y perspectiva.
141. Cunningham, J., Yonkers, K. A., O’Brien, S., & Eriksson, E. (2009). Update on Research and Treatment of Premenstrual Dysphoric Disorder. Harvard Review of Psychiatry. https://doi.org/10.1080/10673220902891836
142. Dahan, A., & Olofsen, E. (2006). Hypercapnia. Wiley Encyclopedia of Biomedical Engineering. https://doi.org/10.1002/9780471740360.ebs0592
143. Daley, D. C., & Douaihy, A. (2019). Managing Cravings and Urges to Use Substances. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926717.003.0009
144. Daley, D. C., & Douaihy, A. (2019). Substance-Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926632.003.0002
145. Dalvi, A., Lyons, K. E., & Pahwa, R. (2006). Secondary Dystonia. CRC Press eBooks. https://doi.org/10.3109/9781420019988-19
146. Dashinie, S., & Renganathan, S. (2014). Major Depressive Disorder without Psychotic Features- A Case Report.
147. Debnath, M. (2021). A Case Report of Non-Reactive Psychosis in a COVID-19 Patient. RECENT ADVANCES IN PATHOLOGY AND LABORATORY MEDICINE. https://doi.org/10.24321/2454.8642.202104
148. Delgado, Y. O., Reyes, A. C., & Imas, Y. A. (2012). Trastorno por estrés agudo: Presentación de un caso. Cuadernos de Medicina Forense. https://doi.org/10.4321/s1135-76062012000100004
149. DeLuca, G. C., & Bartleson, J. D. (2010). When and How to Investigate the Patient with Headache. Seminars in Neurology. https://doi.org/10.1055/s-0030-1249221
150. Derman, E., Whitesman, S., Dreyer, M., Patel, D., Nossel, C., & Schwellnus, M. (2010). Healthy lifestyle interventions in general practice: Part 12: Lifestyle and depression. South African Family Practice. https://doi.org/10.1080/20786204.2010.10873989
151. Dervaux, A. (2013). En quoi et comment le cannabis peut-il être toxique pour le cerveau ?. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2013.09.004
152. Dias, I. M., Maia, I. D., Mello, L. M. R. D., Leite, I. C. G., & Leite, F. P. P. (2014). Evaluation of correlation among sleep bruxism and depression levels, chronic pain and nonspecific physical symptoms according to axis II of the Research Diagnostic Criteria/Temporomandibular disorders. RSBO Revista Sul-Brasileira de Odontologia.
153. Dias, R. D. S. (2010). Estudo comparativo do fenótipo clínico de mulheres com transtorno afetivo bipolar em fase reprodutiva da vida com e sem piora pré-menstrual do humor. https://doi.org/10.11606/t.5.2010.tde-28052010-101220
154. Dilsaver, S. C., Halle, M. H., & Medico, V. J. D. (1991). Symptoms of major depression: acute effect of withdrawing antidepressants. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/j.1600-0447.1991.tb05531.x
155. Dobrea, C., Dell’Osso, B., Carlotta, M., Cremaschi, L., Arici, C., Benatti, B., & Carlo, A. D. (2012). Neuroimaging Data in Bipolar Disorder: An Updated View. InTech eBooks. https://doi.org/10.5772/24566
156. Dougherty, J. W., Ettensohn, M. F., & Levine, S. P. (2018). Beyond Depression: Ketamine and Glutamatergic Agents for PTSD, OCD, and Other Potential Applications. Psychiatric Annals. https://doi.org/10.3928/00485713-20180312-03
157. Douglas, M. E., Kim, B., Mayer, G., Crosby, B., & Towe-Goodm, N. (2012). Maternal Depression, Mothering and Child Development. InTech eBooks. https://doi.org/10.5772/38048
158. Doyle, A., & Pollack, M. H. (2003). Establishment of Remission Criteria for Anxiety Disorders. The Primary Care Companion To The Journal of Clinical Psychiatry.
159. Doyle, A., & Pollack, M. H. (2003). Establishment of remission criteria for anxiety disorders.. PubMed.
160. Dudek, D., & Sobański, J. A. (2012). Mental disorders in somatic diseases: psychopathology and treatment. Polskie Archiwum Medycyny Wewnętrznej. https://doi.org/10.20452/pamw.1539
161. Duma, S., & Fung, V. S. (2019). Drug-induced movement disorders. Australian Prescriber. https://doi.org/10.18773/austprescr.2019.014
162. Dunnigan, M., Czapla, K., Henderson, J. B., & Pelosi, A. J. (1999). The Fluid Retention Syndrome: Recognition, Risk Factors and Management. The Journal of the British Menopause Society. https://doi.org/10.1177/136218079900500206
163. Durán, L. V. B., González, M., & Álvarez, G. B. (2020). Trastorno por estrés postrauma. Revista Medica Sinergia. https://doi.org/10.31434/rms.v5i9.568
164. Duval, F., Jautz-Duval, M. M., González, F., & Rabia, H. (2010). Bases neurobiológicas de vulnerabilidad psiquiátrica a lo largo de las etapas de la vida hormonal de la mujer. Revista chilena de neuro-psiquiatría. https://doi.org/10.4067/s0717-92272010000500005
165. D’Souza, R. S., & Hooten, W. M. (2019). Somatic Syndrome Disorders.
166. Eatmon, C. V., & Daniel, J. (2014). Should You Use an Anticonvulsant to Treat Impulsivity and Aggression. Current psychiatry.
167. Elhassan, N. M., Al‐Salihy, Z., Bushra, M., Sanabel, A.-A., Albobaly, Y., Eltorki, Y., & Alabdulla, M. (2018). Use of Benzodiazepines and Hypnotic Medications in Psychiatry Older Adult Outpatients. International Journal of Case Reports. https://doi.org/10.28933/ijcr-2018-11-1006
168. Elikowski, W., Małek‐Elikowska, M., Fertała, N., & Zawodna-Marszałek, M. (2021). Amiodarone-induced musical hallucinations.. PubMed.
169. Elyasi, F. (2016). Catatonia: extinct, lost, or forgotten?. Journal of Emergency Practice and Trauma. https://doi.org/10.15171/jept.2016.02
170. Enzensperger, C., & Lehmann, J. (2007). Neuroleptika und Antidepressiva als Hypnotika. Wenn Nebenwirkungen zur Hauptwirkung werden. Pharmazie in unserer Zeit. https://doi.org/10.1002/pauz.200600217
171. Ereshefsky, L., Tran-Johnson, T., & Watanabe, M. (1990). Pathophysiologic basis for schizophrenia and the efficacy of antipsychotics.. PubMed.
172. Escobar-Montalvo, J. M., Sanchez, E. H., Petrica, E., & Flor, U. O. D. D. L. (2019). Estado de coma y patrón electroencefalográfico de brote-supresión por sobredosis de Baclofeno.. Revista de Neuro-Psiquiatría. https://doi.org/10.20453/rnp.v82i2.3542
173. Eskander, F. S. L., Hakim, K. Y. K., Ibrahim, D., & ElMallah, W. (2021). Incidence Of Post-Operative Delirium In Geriatric Patients Undergoing Hip Replacement Surgery Using Pre-Operative Haloperidol. QJM. https://doi.org/10.1093/qjmed/hcab086.109
174. Espay, A. J., Fox, S. H., Marras, C., Lang, A. E., & Chen, R. (2007). Isolated diaphragmatic tremor. Neurology. https://doi.org/10.1212/01.wnl.0000267431.16316.69
175. Estroff, T. W., & Gold, M. S. (1985). Medical and Psychiatric Complications of Cocaine Abuse With Possible Points of Pharmacological Treatment. Advances in Alcohol & Substance Abuse. https://doi.org/10.1300/j251v05n01_05
176. Estroff, T. W., & Gold, M. S. (2022). Medical and Psychiatric Complications of Cocaine Abuse With Possible Points of Pharmacological Treatment. Routledge eBooks. https://doi.org/10.4324/9781003282822-6
177. Ettensohn, M. F., Markey, S. M., & Levine, S. P. (2018). Considering Ketamine for Treatment of Comorbid Pain, Depression, and Substance Use Disorders. Psychiatric Annals. https://doi.org/10.3928/00485713-20180312-02
178. Evans, J. J., & Williams, W. H. (2009). Caroline: treating post-traumatic stress disorder after traumatic brain injury. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511581083.017
179. Eşel, E. (2006). [Neurobiology of alcohol withdrawal inhibitory and excitatory neurotransmitters].. PubMed.
180. Fachrudin, D. (2019). Episode Depresif Berat dengan Gejala Psikotik (Studi Kasus dalam Perspektif Psikologi dengan Pendekatan Teori Kognitif Beck). Tunas Medika Jurnal Kedokteran & Kesehatan.
181. Fama, J. M., & Wilhelm, S. (2010). Obsessions. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0616
182. Feder, H. M., & Wormser, G. P. (2021). Studying College Students for the Development of Infectious Mononucleosis and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciab075
183. Feighner, J. P., & Boyer, W. F. (1989). Serotonin-IA Anxiolytics: An Overview. Psychopathology. https://doi.org/10.1159/000284623
184. Fingerhood, M. (2020). Sedatives. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197506172.003.0005
185. Finsterer, J., & Zarrouk‐Mahjoub, S. (2013). Fatigue in Healthy and Diseased Individuals. American Journal of Hospice and Palliative Medicine®. https://doi.org/10.1177/1049909113494748
186. Fischer, T., Agar, M., Hosie, A., & Teodorczuk, A. (2020). Unpacking agitation in practice: a call for greater precision. Age and Ageing. https://doi.org/10.1093/ageing/afaa110
187. Fitzgerald, P. J., & Watson, B. O. (2018). Gamma oscillations as a biomarker for major depression: an emerging topic. Translational Psychiatry. https://doi.org/10.1038/s41398-018-0239-y
188. Flores, C. (2010). FACTORES QUE INFLUYEN EN LA ADICCIÓN ADOLESCENTE. Contribuciones a las Ciencias Sociales.
189. Fraile, I. P., & Mir, M. (2005). Actuación en urgencias ante una crisis convulsiva en adultos. Emergencias: Revista de la Sociedad Española de Medicina de Urgencias y Emergencias.
190. Frean, J., Jong, G. D., & Albrecht, R. (2008). Imaginary bugs, real distress: delusional parasitosis.. PubMed.
191. Freitas, D. F. D., Teixeira-Ribeiro, R., Bouça, J., Fernandes, N., Duarte, J., & Morgado, P. (2015). Metformin-induced Psychosis: a Case Report.. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)31423-1
192. Funk, S. (2013). [Pharmacological treatment in alcohol-, drug- and benzodiazepine-dependent patients - the significance of trazodone].. PubMed.
193. Galasko, D. (2019). Pharmacological Approaches To Behavioral Symptoms In Alzheimer’s Disease. CRC Press eBooks. https://doi.org/10.1201/9780429260353-28
194. Garay, M. A., Richards, S., Mj, M. U., & Luguercho, C. (2007). [Psychotic major depressive episode: target symptoms in males and females].. PubMed.
195. Garcia, M. O., Garnica, M. M., Marin, S. G., Martínez, C., Martínez, R. G., & Valle, P. B. D. (2017). A child with Pica. A case presentation. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.472
196. García, E., García, L. C., Villarroel, C. M., Revuelta, M. S., Cutanda, J. D., & Matsuura, J. (2021). Obsessive symptoms as first alert of psychosis: Two cases report. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2021.1625
197. García, M. D. S., & Calderón, R. M. (2010). Síntomas no motores en la enfermedad de Parkinson y estimulación cerebral profunda. Revista de Neurología. https://doi.org/10.33588/rn.50s02.2009745
198. García, R. G., Alvarez, M. R., & Arturo, F. (2010). Cefalea por uso excesivo de medicamentos: implicaciones clínicas y terapéuticas Medication over use headache: clinical and therapeutic implications.
199. Gardner, M. E. (1995). Drug Therapy of Aggressive Behaviors Accompanying Dementia. Journal of Pharmacy Practice. https://doi.org/10.1177/089719009500800503
200. Gautam, S., Jain, A., Gautam, M., Vahia, V., & Gautam, A. (2017). Clinical Practice Guidelines for the Management of Generalised Anxiety Disorder (GAD) and Panic Disorder (PD). Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.196975
201. Gay, C. (2009). [Atypical bipolar disorders].. PubMed.
202. Genovese, J. P. S., Almenar, R. A., & Veintimilla, M. C. A. (2013). A propósito de un caso de patología dual. Trastorno bipolar tipo I. Dependencia a cocaína y alcohol.
203. Geoffroy, P. A., Rolland, B., & Cottencin, O. (2012). Catatonia and Alcohol Withdrawal: A Complex and Underestimated Syndrome. Alcohol and Alcoholism. https://doi.org/10.1093/alcalc/agr170
204. Ghaemi, S. N. (2018). Children. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199995486.003.0028
205. Ghaemi, S. N. (2018). Dopamine Blockers (“Antipsychotics”). Oxford University Press eBooks. https://doi.org/10.1093/med/9780199995486.003.0010
206. Giacobbe, P., & Flint, A. J. (2007). Pharmacological treatment of poststroke pathological laughing and crying. Journal of Psychiatry and Neuroscience. https://doi.org/10.1139/jpn.0737
207. Giannuzzi, R., Testa, A. C., Sollazzo, F., Petrongolo, L., Bernardini, L., & Daini, S. (2013). Psychiatric emergencies (part I): psychiatric disorders causing organic symptoms.. PubMed.
208. Giliberti, A., Frisina, A. M., Giustiniano, S., Carbonaro, Y., Roccella, M., & Nardello, R. (2025). Autism Spectrum Disorder and Epilepsy: Pathogenetic Mechanisms and Therapeutic Implications. Journal of Clinical Medicine. https://doi.org/10.3390/jcm14072431
209. Gitlin, M. (1995). Effects of depression and antidepressants on sexual functioning.. PubMed.
210. Glance, J., Gopalan, P., & Ackerman, K. D. (2015). Substance Intoxication and Withdrawal States in the General Medical Setting. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199329311.003.0016
211. Glasgow, H. B., Burkholder, J. M., Schmechel, D. E., Tester, P. A., & Rublee, P. A. (1995). Insidious effects of a toxic estuarine dinoflagellate on fish survival and human health. Journal of Toxicology and Environmental Health. https://doi.org/10.1080/15287399509532051
212. Gordon, M. F., & Leder, A. (2012). Serotonin Syndrome. Humana Press eBooks. https://doi.org/10.1007/978-1-60761-835-5_18
213. Graddy, R., & Rastegar, D. A. (2020). Stimulants. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197506172.003.0008
214. Graddy, R., & Rastegar, D. A. (2025). Stimulants. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197796207.003.0008
215. Granger, C. E., & Shelly, M. P. (1996). Stressing out, or outing stress?. European Journal of Anaesthesiology. https://doi.org/10.1097/00003643-199611000-00001
216. Grannell, L. (2020). Drug interaction resources: mind the gaps. Australian Prescriber. https://doi.org/10.18773/austprescr.2020.005
217. Grant, P., & Ireland, A. J. (1994). Decerebrate posturing in alcoholic coma.. Emergency Medicine Journal. https://doi.org/10.1136/emj.11.3.206
218. Graziottin, A., & Serafini, A. (2009). Depression and the menopause: why antidepressants are not enough?. Menopause international. https://doi.org/10.1258/mi.2009.009021
219. Greden, J. F., Dilsaver, S. C., & Snider, R. M. (1987). Antidepressant Withdrawal Syndromes: Phenomenology and Pathophysiology. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-198701000-00001
220. Greydanus, D. E., Calles, J. L., & Patel, D. R. (2008). Anxiety disorders. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544705.007
221. Griffiths, M. D., Hodgson, R. J., & Budd, R. (2001). Compulsive Behaviours. Contemporary psychiatry. https://doi.org/10.1007/978-3-642-59519-6_131
222. Groisman, A. E., & Seminatore, M. L. (2003). Children and Adolescents Who Have Schizophrenia. Pediatrics in Review. https://doi.org/10.1542/pir.24.10.356
223. Grossman, M. N. (2021). Several weeks of low mood, decreased appetite, and poor sleep after changing schools. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0007
224. Guamanarca, R. I. S., Loraque, N. B., Rubio, A. L., García, M. M., Lupiañez, I. J., & Llaría, M. M. M. (2025). SÍNDROME DE EKBOM EN PACIENTE GERIÁTRICO. A PROPÓSITO DE UN CASO.. Revista sanitaria de investigación.. https://doi.org/10.34896/rsi.2025.31.47.002
225. Gupta, K., & Mamidi, P. (2020). Vataja Unmada: Schizophrenia or Dementia or Mood Disorder with Psychosis?. International Journal of Yoga - Philosophy Psychology and Parapsychology. https://doi.org/10.4103/ijny.ijoyppp_24_19
226. Guskiewicz, K. M., & Goldman, S. B. (2013). A Changing Landscape: Traumatic Brain Injury in Military Combat and Civilian Athletics. The FASEB Journal. https://doi.org/10.1096/fj.13-1101ufm
227. Guthrie, E., & Nayak, A. (2012). Medically unexplained symptoms.
228. Gómez‐Revuelta, M., Blanco, L. S., Ruíz, M. J., Jenaro, G. P. D. S., Rodríguez, R. L., Olivares, O. P., & Morales, N. N. (2017). A Clinical review about differential diagnosis and comorbidities on premenstrual dysphoric disorder. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.577
229. Güleç, H., Babayiğit, M., Kurtay, A., Şahap, M., Ulus, F., Tutal, Z. B., & Horasanlı, E. (2014). Seizure due to multiple drugs intoxication: a case report. Brazilian Journal of Anesthesiology (English Edition). https://doi.org/10.1016/j.bjane.2014.02.013
230. Haffner, C. A., & Kendall, M. J. (2020). The Acute Unwanted Effects of Beta2 Receptor Agonist Therapy. CRC Press eBooks. https://doi.org/10.1201/9780429281082-13
231. Hainline, B., Gurin, L., & Torres, D. M. (2019). Concussion Two Weeks Later. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0007
232. Halaby, A., Haddad, R., & Naja, W. (2013). Non-Antidepressant Treatment of Social Anxiety Disorder: A Review. Current Clinical Pharmacology. https://doi.org/10.2174/15748847113089990059
233. Hale, A. S. (1997). ABC of mental health: Anxiety. BMJ. https://doi.org/10.1136/bmj.314.7098.1886
234. Hall, W., Talbert, R. L., & Ereshefsky, L. (1990). Cocaine Abuse and Its Treatment. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/j.1875-9114.1990.tb02550.x
235. Hamdan, M., & Machin, A. (2009). Restless Legs Syndrome. Airlangga University Press eBooks.
236. Hardman, M. I., Šprung, J., & Weingarten, T. N. (2018). Acute phenibut withdrawal: A comprehensive literature review and illustrative case report. Bosnian Journal of Basic Medical Sciences. https://doi.org/10.17305/bjbms.2018.4008
237. Haro, G. (2012). New Clinical Implications of Opiate Maintenance Treatments. international journal high risk behaviors & addiction. https://doi.org/10.5812/ijhrba.6532
238. Hauser, R. A., Meyer, J. M., Factor, S. A., Comella, C., Tanner, C. M., Xavier, R. M., Caroff, S. N., & Lundt, L. (2020). Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. CNS Spectrums. https://doi.org/10.1017/s109285292000200x
239. Hawes, D. J., & Scalise, P. (2005). Childhood depression: early risk and resilience and introducing solids to infants. https://doi.org/10.4225/50/5552facc15227
240. Hawkes, M. A., & Hocker, S. E. (2021). Status Epilepticus. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197512166.003.0057
241. Heinz, A. (2002). Dopaminergic dysfunction in alcoholism and schizophrenia – psychopathological and behavioral correlates. European Psychiatry. https://doi.org/10.1016/s0924-9338(02)00628-4
242. Hemmingsen, R., Kramp, P., & Rafaelsen, O. J. (1983). Organic cerebral reactions in alcoholism: psychobiological aspects of treatment.. PubMed.
243. Henkin, R. I., & Abdelmeguid, M. (2020). Smell Loss and Onset of Phantosmia are Critical Aspects of Head Injury Cognition. The FASEB Journal. https://doi.org/10.1096/fasebj.2020.34.s1.02320
244. Hernández, Y. D. C. S. (2016). Alteraciones estructurales de las regiones cerebrales sexuales tras empleo de paroxetina versus agomelatina. https://doi.org/10.14201/gredos.129703
245. Hershkowitz, E., Reshef, A., Munich, O., Yosefi, B., & Markel, A. (2014). Thiamine Deficiency in Self-Induced Refeeding Syndrome, an Undetected and Potentially Lethal Condition. Case Reports in Medicine. https://doi.org/10.1155/2014/605707
246. Hertz, L., Song, D., Li, B., Du, T., Xu, J., Gu, L., Chen, Y., & Liang, P. (2014). Signal Transduction in Astrocytes during Chronic or Acute Treatment with Drugs (SSRIs, Antibipolar Drugs, GABA-ergic Drugs, and Benzodiazepines) Ameliorating Mood Disorders. Journal of Signal Transduction. https://doi.org/10.1155/2014/593934
247. Higuchi, H., Shimizu, T., & Hishikawa, Y. (1997). Recurrent paroxysmal episodes characterized by perceptual alteration in three schizophrenic patients on neuroleptic medication. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/j.1440-1819.1997.tb02369.x
248. Hillman, D. R., Carlucci, M., Charchaflieh, J., Cloward, T. V., Gali, B., Gay, P. C., Lyons, M. M., McNeill, M. M., Singh, M., Yılmaz, M., & Auckley, D. (2023). Society of Anesthesia and Sleep Medicine Position Paper on Patient Sleep During Hospitalization. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0000000000006395
249. Hirose, S. (2001). Restlessness related to SSRI withdrawal. Psychiatry and Clinical Neurosciences. https://doi.org/10.1046/j.1440-1819.2001.00789.x
250. Hirose, S. (2003). The Causes of Underdiagnosing Akathisia. Schizophrenia Bulletin. https://doi.org/10.1093/oxfordjournals.schbul.a007027
251. Hocker, S. E., Wijdicks, E. F. M., & Rabinstein, A. A. (2013). Refractory status epilepticus: new insights in presentation, treatment, and outcome. Neurological Research. https://doi.org/10.1179/1743132812y.0000000128
252. Hollister, L. E. (1990). New class of hallucinogens: GABA‐enhancing agents. Drug Development Research. https://doi.org/10.1002/ddr.430210311
253. Holloman, L. C., & Marder, S. R. (1997). Management of acute extrapyramidal effects induced by antipsychotic drugs. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/54.21.2461
254. Homberg, J. R., & Contet, C. (2009). Deciphering the Interaction of the Corticotropin-Releasing Factor and Serotonin Brain Systems in Anxiety-Related Disorders: Figure 1.. Journal of Neuroscience. https://doi.org/10.1523/jneurosci.4362-09.2009
255. Hong, C. (2013). 분과 심포지움 2. 임상 : 새로운 진단체계 DSM-5; 조현병 스펙트럼 및 기타 정신병적 장애,성격장애. 한국심리학회 연차 학술발표논문집.
256. Hong, C. (2013). 조현병 스펙트럼 및 기타 정신병적 장애, 성격장애. 한국심리학회 학술대회 자료집.
257. Hong, I. S., & Bishop, J. R. (2014). Geriatric Patients: Choose Wisely: Age-Related Physiologic Changes, Risk of Adverse Effects Guide Your Prescribing. Current psychiatry.
258. Horn, J. B., Zandbergen, E., Koelman, J., & Hijdra, A. (2008). Prognosis for patients in a coma following cardiopulmonary resuscitation.
259. Houdenhove, B. V., Pae, C., & Luyten, P. (2010). Chronic fatigue syndrome: is there a role for non-antidepressant pharmacotherapy?. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656560903487744
260. Hsieh, M. T., Peng, W., Wu, C., Ng, K., Cheng, C. Y., & Xu, H. (2010). None. Planta Medica. https://doi.org/10.1055/s-002-20741
261. Huprich, S. K. (2010). Schizoid Personality Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0819
262. Häuser, W. (2016). Fibromyalgia syndrome: Basic knowledge, diagnosis and treatment.. PubMed.
263. Iliev, B., & Pavlovska, I. (2021). Analysis of Clinical Features of Patients with Depressive Disorder. Journal of Health Medicine and Nursing. https://doi.org/10.7176/jhmn/92-01
264. Impey, B., Gordon, R. P., & Baldwin, D. S. (2020). Anxiety disorders, post-traumatic stress disorder, and obsessive–compulsive disorder. Medicine. https://doi.org/10.1016/j.mpmed.2020.08.005
265. Ingrassia, G. F. (2012). HISTORICAL EVOLUTION OF MEDICAL KNOWLEDGE IN THE FIELD OF VEGETATIVE STATE.
266. Inmaculada, M., & Pérez, P. B. (2016). Neuronal and behavioural effects of social isolation in old age.
267. Isobe, T., Sato, H., Goto, T., Yako, T., Yoshida, K., & Hashimoto, T. (2019). Supplementary Material for: Long-Term Suppression of Disabling Tremor by Thalamic Stimulation in a Patient with Spinocerebellar Ataxia Type 2. Figshare. https://doi.org/10.6084/m9.figshare.10331774
268. Iversen, L. L., Iversen, S. D., Bloom, F. E., & Roth, R. H. (2009). Psychedelics. Oxford University Press eBooks. https://doi.org/10.1093/med/9780195380538.003.0606
269. İnce, C., Karakuş, M., Karadeniz, S., & Kandil, S. (2014). Atomoksetin Kullanımı Sırasında Gelişen Bir Obsesif Kompulsif Bozukluk Olgusu. Turkish Journal of Pediatric Disease.
270. Jablensky, A. (2012). Course and outcome of schizophrenia and their prediction. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0078
271. Jahan, A. R., & Burgess, D. M. (2021). Substance Use Disorder. StatPearls.
272. Jalal, B. (2018). The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug. Psychopharmacology. https://doi.org/10.1007/s00213-018-5042-1
273. James, F. O. (2016). First Line Antidepressant Medications: Brief Overview of Underlining Mechanisms. SM Journal of Depression Research and Treatment. https://doi.org/10.36876/smjdrt.1013
274. Janicak, P. G. (2014). Pharmacological Treatment of Psychosis. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg11
275. Jargin, S. V. (2019). Some aspects of tobacco smoking in the context of alcohol drinking, hangover and mental health problems. International Journal of Psychiatry Research. https://doi.org/10.33545/26648962.2019.v1.i2a.10
276. Jevtovic, J., Jovanović, J., Grujicic, M. V. –., & Vujcic, J. (2021). OCCUPATIONAL STRESS IN COMPUTER OPERATORS. Knowledge International Journal.
277. Jiménez, C., & Belén, M. (2019). Terapia de aceptación y compromiso grupal aplicada a pacientes adictos a los opioides con el manejo de los síntomas de abstinencia junto con la terapia farmacológica para evitar recaídas a futuro.
278. Johnston, M. P., & Coward, D. D. (2001). Cancer-Related Fatigue: Nursing Assessment and Management. AJN American Journal of Nursing. https://doi.org/10.1097/00000446-200104001-00005
279. Kalivas, P. W. (2003). Development and Expression of Behavioral Sensitization. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-343-9_9
280. Kalivas, P. W., Toda, S., Bowers, M. S., Baker, D. L., & Ghasemzadeh, M. B. (2003). The Temporal Sequence of Changes in Gene Expression by Drugs of Abuse. Humana Press eBooks. https://doi.org/10.1385/1-59259-358-5:03
281. Kalsi, S. S., Wood, D. M., & Dargan, P. I. (2011). The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerging Health Threats Journal. https://doi.org/10.3402/ehtj.v4i0.7107
282. Karakatsoulis, G. N., Tsapakis, E.-M., & Fountoulakis, K. Ν. (2021). Clinical characteristics and treatment of treatment-resistant bipolar depression. Psychiatriki. https://doi.org/10.22365/jpsych.2021.048
283. Karila, L., Lowenstein, W., Coscas, S., Benyamina, A., & Reynaud, M. (2009). [Complications of cocaine addiction].. PubMed.
284. Karssemeijer, E. G., Heijden, C. D. V. D., Wolters, T. L. C., Boekhorst, B. T., Avest, M. T., & Kramers, C. (2021). [Don't stop medication too abruptly: advice about the discontinuation of medication]..
285. Karssemeijer, E. G., Heijden, C. D. V. D., Wolters, T. L. C., Boekhorst, B. T., Avest, M. T., & Kramers, C. (2021). [Don't stop medication too abruptly: advice about the discontinuation of medication].. PubMed.
286. Katic, A., & Vinall, P. (2009). A Review of Recent Studies of Lisdexamfetamine Dimesylate for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children. MD Conference Express. https://doi.org/10.1177/155989770903006
287. Katzman, M. A. (2021). The Diagnosis of Major Depressive Disorder is based on the Person's Reported Experiences and a Mental Status Examination. Journal of Aging and Geriatric Medicine.
288. Kazymova, N., Kharlamenkova, N. Y., & Nikitina, D. A. (2019). Severe life events and their psychological consequences: loss or threat of loss of nearest. Vestnik Kostroma State University Series Pedagogy Psychology Sociokinetics. https://doi.org/10.34216/2073-1426-2019-25-2-96-101
289. Keith, S. J. (2007). Dual Diagnosis of Substance Abuse and Schizophrenia: Improving Compliance with Pharmacotherapy. Clinical Schizophrenia & Related Psychoses. https://doi.org/10.3371/csrp.1.3.5
290. Kelly, F. D. (2010). Adjustment Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0015
291. Kemp, D. E. (2014). Managing the side effects associated with commonly used treatments for bipolar depression. Journal of Affective Disorders. https://doi.org/10.1016/s0165-0327(14)70007-2
292. Kennedy, J. E., Jaffee, M. S., & Cooper, D. (2013). Posttraumatic Stress Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625154.da08
293. Kennedy, S. H. (2008). Core symptoms of major depressive disorder: relevance to diagnosis and treatment. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2008.10.3/shkennedy
294. Khan, I., & Khan, M. A. (2021). Sensory and Perceptual Alterations. StatPearls.
295. Khantzian, E. J. (1990). Self-regulation and self-medication factors in alcoholism and the addictions. Similarities and differences.. PubMed.
296. Kim, G. S., Nunez, T., & Vargas, E. (2021). Omeprazole-induced Visual Hallucinations: A Case Report. Journal of Psychiatric Practice. https://doi.org/10.1097/pra.0000000000000575
297. Kim, G.-M., Jeong, W., & Hwang, T. (2019). Depression and Gap between Perceived- and Self-Willingness-to-Pay for Labor in Community-Dwelling Full-Time Female Homemakers. Journal of Korean Neuropsychiatric Association. https://doi.org/10.4306/jknpa.2019.58.4.322
298. Kim, H. A., Bisdorff, A., Bronstein, A. M., Lempert, T., Rossi-Izquierdo, M., Staab, J. P., Strupp, M., & Kim, J. (2019). Hemodynamic orthostatic dizziness/vertigo: Diagnostic criteria. Journal of Vestibular Research. https://doi.org/10.3233/ves-190655
299. Kim, J.-Y. (2006). 분노증세를 동반한 심인성 진전 환자에 대해 이완요법과 한방치료를 실시한 1례 보고. 동의신경정신과학회지.
300. Kim, S.-H., Park, S.-J., Byun, S.-I., Kim, J., Kim, J.-W., Chung, S.-Y., Hwang, W.-W., & Kim, J.-H. (2006). Relaxation Training for psychogenic tremor patient with anger : A Case Report. The Korean Society of Oriental Neuropsychiatry.
301. Kintz, P., Villain, M., Cirimele, V., Goullé, J., & Ludes, B. (2002). [Crime under the influence of psychoactive drugs: the problem of the duration of detection].. PubMed.
302. Kircus, E., & Brillhart, B. (1990). Dealing with Substance Abuse Among People with Disabilities. Rehabilitation Nursing. https://doi.org/10.1002/j.2048-7940.1990.tb01487.x
303. Kirov, K. (1989). Aggressiveness, Anxiety and Drugs. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.155.6.846
304. Klein, C., & Myers, M. F. (2009). Afraid to Leave Home. Current psychiatry.
305. Klein, D. F., & Wender, P. H. (2005). Symptoms of Mood Disorders: Recognizing Biological Depression. https://doi.org/10.1093/oso/9780195156133.003.0002
306. Kocsis, J. H., Francés, A., Marin, D. B., Manning, D. W., Markowitz, J. C., Mason, B. J., & Widiger, T. A. (2007). Diagnostic criteria for 300.4 Dysthymic Disorder. American Psychiatric Association eBooks. https://doi.org/10.1176/appi.books.9780890423349.2412
307. Kodela, S., & Venkata, P. D. (2010). Antidepressant induced apathy responsive to dose reduction.. PubMed.
308. Koh, R. Y., Chew, Z. X., Lim, C. L., Ng, K. Y., Chye, S. M., & Ling, A. P. K. (2021). The Role of Monoamine Oxidase B Inhibitors in the Treatment of Parkinson’s Disease - An Update. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/1871527321666211231100255
309. Koob, G. F. (2020). Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development. Pharmacological Reviews. https://doi.org/10.1124/pharmrev.120.000083
310. Koob, G. F., Kandel, D. B., Baler, R., & Volkow, N. D. (2015). Pathophysiology of Addiction. Psychiatry. https://doi.org/10.1002/9781118753378.ch22
311. Kora, K., & Kaplan, P. (2008). [Hypomania/mania induced by cessation of antidepressant drugs].. PubMed.
312. Korff, M. V., & Simon, G. (1996). The Relationship Between Pain and Depression. The British Journal of Psychiatry. https://doi.org/10.1192/s0007125000298474
313. Krahn, L. E., MD, & Jowsey‐Gregoire, S. G. (2006). Psychiatry. CRC Press eBooks. https://doi.org/10.1201/b21610-26
314. Ksiądzyna, D., Merwid‐Ląd, A., Matuszewska, A., Grotthus, B., & Szeląg, A. (2019). Objawy odstawienia wybranych leków. Część I. Medycyna Rodzinna. https://doi.org/10.25121/mr.2019.22.1.27
315. Ksiądzyna, D., Merwid‐Ląd, A., Matuszewska, A., Grotthus, B., & Szeląg, A. (2019). Objawy odstawienia wybranych leków. Część II. Medycyna Rodzinna. https://doi.org/10.25121/mr.2019.22.1.33
316. Kumar, A. (2019). None. Current Trends On Biotechnology & Microbiology Open Access Publishers. https://doi.org/10.32474/ctbm.1.2
317. Kumar, P. S., Krishnan, A., & Suresh, R. (2019). Escitalopram-induced extrapyramidal symptoms. Indian Journal of Psychiatry. https://doi.org/10.4103/psychiatry.indianjpsychiatry_331_18
318. Kumar, S., & Browne, M. O. (2003). What are the effects of drug treatments for panic disorder?. Evidence-Based Mental Health. https://doi.org/10.1136/ebmh.6.2.34
319. Kuzminov, V. (2019). he dependence of the clinical picture of acute psychosis connected with alcohol withdrawal from the forms of alcohol consumption. Ukrains kyi Visnyk Psykhonevrolohii. https://doi.org/10.36927/2079-0325-v27-is1-2019-16
320. Lahey, B. B. (2021). Dimensions of Externalizing Problems. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197607909.003.0004
321. Lam, R. W. (2018). Associated clinical features. Depression. https://doi.org/10.1093/med/9780198804147.003.0005
322. Lam, R. W. (2018). Clinical features and diagnosis. Depression. https://doi.org/10.1093/med/9780198804147.003.0004
323. Lane, R., & Baldwin, D. S. (1997). Selective Serotonin Reuptake Inhibitor-Induced Serotonin Syndrome. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199706000-00012
324. Lanièpce, A., Cabé, N., André, C., Bertran, F., Boudehent, C., Lahbairi, N., Maillard, A., Mary, A., Segobin, S., Vabret, F., Rauchs, G., & Pitel, A. (2020). The effect of alcohol withdrawal syndrome severity on sleep, brain and cognition. Brain Communications. https://doi.org/10.1093/braincomms/fcaa123
325. Lanzaro, M. (2017). A new syndrome? The sport identification addiction and the case of Italian football ultra-fanatical support. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.508
326. Laqueille, X., Uribe-Restrepo, J. M., & Olié, J. P. (1995). [Current clinical aspects of drug addiction].. PubMed.
327. Lasocka, M., Konopko, M., Basińska-Szafrańska, A., Rogowski, A., & Sienkiewicz‐Jarosz, H. (2020). Seizures in alcohol withdrawal syndrome. Aktualności Neurologiczne. https://doi.org/10.15557/an.2020.0008
328. Latt, N., Conigrave, K. M., Saunders, J. B., Marshall, E. J., & Nutt, D. (2009). Chapter 10 Other drugs. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199539338.003.0010
329. Lawrie, S. M. (2010). Schizophrenia, bipolar disorder, obsessive–compulsive disorder, and personality disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199204854.003.260507
330. Ledezma, C., Soto, K., & Suárez, M. I. (2015). Depresión en el adulto mayor en Costa Rica: un problema social. Revista Hispanoamericana de Ciencias de la Salud.
331. Leiblum, S. R. (2003). Arousal disorders in women: complaints and complexities. The Medical Journal of Australia. https://doi.org/10.5694/j.1326-5377.2003.tb05392.x
332. Lembo, D., Prosperi, I., & Fabrizi, A. (2009). Una nuova disfunzione sessuale femminile: Il Disturbo da Eccitazione Sessuale Persistente (PSAD). RIVISTA DI SESSUOLOGIA CLINICA. https://doi.org/10.3280/rsc2009-002003
333. Lepping, P., Huber, M., & Freudenmann, R. W. (2015). How to approach delusional infestation. BMJ. https://doi.org/10.1136/bmj.h1328
334. Lhommée, E., Klinger, H., Thobois, S., Schmitt, E., Ardouin, C., Bichon, A., Kistner, A., Fraix, V., Xie, J., Kombo, M. A., Chabardès, S., Seigneuret, É., Benabid, A., Mertens, P., Polo, G., Carnicella, S., Quésada, J.-L., Bosson, J., Broussolle, E., ... Krack, P. (2012). Subthalamic stimulation in Parkinson’s disease: restoring the balance of motivated behaviours. Brain. https://doi.org/10.1093/brain/aws078
335. Ligier, F., & Kabuth, B. (2016). Between Neurology and Psychiatry, a Difficult Preliminary Diagnosis of Kleine-levin Syndrome: Case-report of a Young Girl. Journal of Child and Adolescent Behaviour. https://doi.org/10.4172/2375-4494.1000274
336. Lim, H., Kwon, Y.-J., Lee, J.-E., & Cho, S. (2013). Reconsideration of Psychasthenia- Two Cases. Journal of Oriental Neuropsychiatry. https://doi.org/10.7231/jon.2013.24.3.245
337. Limandri, B. J. (2018). Insomnia: Will Medication Bring Rest?. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/02793695-20180619-03
338. Lockhart, P. J. (2001). Fetal alcohol spectrum disorders for mental health professionals - a brief review. Current Opinion in Psychiatry. https://doi.org/10.1097/00001504-200109000-00007
339. Loconte, S. (2019). Primary fibromyalgia syndrome: A new holistic approach [abstract]. Journal of Ozone Therapy. https://doi.org/10.7203/jo3t.3.4.2019.15526
340. Logan, B. K., & Couper, F. J. (2003). 3,4-Methylenedioxymethamphetamine - Effects on Human Performance and Behavior.. PubMed.
341. Lovina, L. (2021). The Use of Ketamine as Therapy for Depression. Open Access Indonesian Journal of Medical Reviews. https://doi.org/10.37275/oaijmr.v1i2.34
342. Lozano, R. P., García, Y. Á., Tafalla, D. B., & Albaladejo, M. F. (2007). Cafeína: un nutriente, un fármaco, o una droga de abuso. Adicciones. https://doi.org/10.20882/adicciones.303
343. Luisetto, M. (2018). Mindset kinetics and Some Depression Status: A New Quantitative Model Under Biochemical-Toxicology Approach?. Journal of pharmacology & clinical research. https://doi.org/10.19080/jpcr.2018.05.555680
344. Luthra, M. (2017). Depression: Current Scenario with reference to India. Indian Journal of Community Health. https://doi.org/10.47203/ijch.2017.v29i01.001
345. López, A. M., Martínez, L. R. D., & Moreno, J. (2012). Uso de marcadores bioquímicos para valoración de riesgo de crisis convulsivas en el síndrome de supresión etílica. Salud Mental.
346. Macenski, C. L. (2021). Recurrent episodes of binging and purging. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0024
347. Mackenzie, I. S., & Brown, M. J. (2007). Pseudopheochromocytoma. Journal of Hypertension. https://doi.org/10.1097/hjh.0b013e3282f0fdbc
348. Macneil, C., Hasty, M., Conus, P., Berk, M., & Scott, J. (2009). Social rhythm regulation. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511757389.008
349. Macovei, A. L., Dobrin, I., Chiriță, V., Burlui, A., Dobrin, P.-R., & Rezuş, E. (2019). Chronic fatigue and psychiatric comorbidities in patients with rheumatic disorders. Bulletin of Integrative Psychiatry. https://doi.org/10.36219/bpi.2019.03.08
350. MacPherson, H. A. (2019). More than medication: The importance of family treatments for pediatric bipolar disorder. The Brown University Child and Adolescent Behavior Letter. https://doi.org/10.1002/cbl.30433
351. Madhavan, J. (2017). Ayurvedic Approach to Alcohol Withdrawal Syndrome. International Journal of Complementary & Alternative Medicine. https://doi.org/10.15406/ijcam.2017.07.00226
352. Madruga, M. L. L. H., Melo, G. B., Martins, J. M., Aranha, R. E. L. D. B., Marinho, J. C. R. L., Alves, N. T., Estudo, E., Revisão, U., & Literatura, D. (2018). Estudo Eletroencefalográfico De Indivíduos Com Dor Crônica Decorrente Da Fibromialgia: Uma Revisão Da Literatura. Scientific Research and Reviews. https://doi.org/10.28933/srr-2018-06-28100
353. Mahadevan, J., D’cruz, M., Chand, P., & Murthy, P. (2019). An interesting presentation of psychotic catatonia in an elderly patient with alcohol dependence. Journal of Geriatric Mental Health. https://doi.org/10.4103/jgmh.jgmh_33_19
354. Mahato, T. K., Ojha, S. K., Singh, V., & Parihar, S. P. S. (2021). Addiction withdrawal syndrome: Needs medications, education, counselling &amp; support. World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2021.12.2.0573
355. Majewska, M. (1996). Cocaine Addiction as a Neurological Disorder: Implications for Treatment. PsycEXTRA Dataset. https://doi.org/10.1037/e495672006-002
356. Manfredini, R., Cecilia, L., Boari, B., & Gallerani, M. (2001). [Epistaxis and circadian rhythm].. PubMed.
357. Manica, A., Leães, C. G. S., Frey, B. N., & Juruena, M. F. (1999). The role of depression in coronary artery disease. Arquivos Brasileiros de Cardiologia. https://doi.org/10.1590/s0066-782x1999000800012
358. Maramis, M. M. (2009). Mengenal Gangguan Mood pada Perempuan.
359. Marcello, S., & Silverstein, S. M. (2010). Schizophrenia. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0820
360. Mardani, M. (2017). Can Antibiotic Induce Mental Status Change?. Archives of Clinical Infectious Diseases. https://doi.org/10.5812/archcid.45895
361. Maremmani, I., Pacini, M., Lamanna, F., Pani, P., Perugi, G., Deltito, J., Salloum, I. M., & Akiskal, H. S. (2010). Mood Stabilizers in the Treatment of Substance Use Disorders. CNS Spectrums. https://doi.org/10.1017/s1092852900027346
362. Markham, R. A., & Watts, S. (2005). Etiology of Depression in Children.. Journal of instructional psychology.
363. Martin, C. M. (2007). &lt;b&gt;It's Nothing to Laugh About: Understanding Disorders of Emotional Expression&lt;/b&gt;. The Consultant Pharmacist. https://doi.org/10.4140/tcp.n.2007.732
364. Martins, S. F., Quarenta, J., Teixeira, T., & Ribeiro, J. (2021). Cocaine bugs: A brief case report of cocaine-induced delusion of parasitosis. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2021.1708
365. Mast, R., Harper, B., Pollock, K., & Gentile, J. P. (2019). Pharmacologic Treatment of Attention Deficit Disorder in Children and Adolescents: Executive Function Agents, Stimulants, and Sympathomimetic Amines. Journal of Clinical Medicine and Therapeutics.
366. Mattison, A., & Cherner, M. (2005). Club drugs and HIV transmission. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198526100.003.0067
367. Mattson, R. H. (1990). Selection of Drugs for the Treatment of Epilepsy. Seminars in Neurology. https://doi.org/10.1055/s-2008-1063985
368. Mauri, M. C. (2016). Drug Induced Psychosis or Schizophrenia?. Dual Diagnosis Open Access. https://doi.org/10.21767/2472-5048.100011
369. Mavrogiorgou, P., Juckel, G., & Bauer, M. (2001). Rezidivierende paranoid-halluzinatorische Psychose nach Beginn einer Hungerkur bei einer Patientin mit Anorexia nervosa. Fortschritte der Neurologie · Psychiatrie. https://doi.org/10.1055/s-2001-13932
370. McIntosh, C., & Ritson, B. (2001). Treating depression complicated by substance misuse. Advances in Psychiatric Treatment. https://doi.org/10.1192/apt.7.5.357
371. McKetin, R. (2018). Methamphetamine psychosis: insights from the past. Addiction. https://doi.org/10.1111/add.14170
372. Medina, S., & Fernando, D. (2019). Caso Christopher : El deseo, de deseo imposible en la neurosis obsesiva..
373. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). [Clinical practice guideline. Diagnosis and treatment of insomnia in the elderly].. PubMed.
374. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). Diagnóstico y tratamiento del insomnio en el adulto mayor.
375. Meehan, T. J., Bryant, S. M., & Aks, S. E. (2010). Drugs of Abuse: The Highs and Lows of Altered Mental States in the Emergency.
376. Meeusen, R., Cutsem, J. V., & Roelands, B. (2020). Endurance exercise‐induced and mental fatigue and the brain. Experimental Physiology. https://doi.org/10.1113/ep088186
377. Mendez, M. F. (2017). What is the Relationship of Traumatic Brain Injury to Dementia?. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-161002
378. Mercês, T. M. D. (2019). Controle hidroeletrolítico e respostas cardiovasculares à injeção central de angII, carbacol e hiperosmolaridade plasmática em ratos com epilepsia induzida por pilocarpina.
379. Merlo, L. J., & Storch, E. A. (2006). Obsessive-compulsive disorder: tools for recognizing its many expressions.. PubMed.
380. Meyer, J. S., & Hamel, A. F. (2014). Models of Stress in Nonhuman Primates and Their Relevance for Human Psychopathology and Endocrine Dysfunction. ILAR Journal. https://doi.org/10.1093/ilar/ilu023
381. Michel, B. (2018). Postpartum depression: An overview. Archives of Depression and Anxiety. https://doi.org/10.17352/2455-5460.000035
382. Michie, S. (2002). CAUSES AND MANAGEMENT OF STRESS AT WORK. Occupational and Environmental Medicine. https://doi.org/10.1136/oem.59.1.67
383. Mihaljević, S., Pavlović, M., Reine, K., & Čačić, M. (2020). THERAPEUTIC MECHANISMS OF KETAMINE. Psychiatria Danubina. https://doi.org/10.24869/psyd.2020.325
384. Mihaljević, S., Pavlović, M., Reiner, K., & Čačić, M. (2020). THERAPEUTIC MECHANISMS OF KETAMINE. https://doi.org/10.31219/osf.io/5xryf
385. Mihanović, M., Bodor, D., Kezić, S., Restek-Petrović, B., & Silić, A. (2009). Differential diagnosis of psychotropic side effects and symptoms and signs of psychiatric disorders.. PubMed.
386. Mikkelsen, M. E., & Iwashyna, T. J. (2020). Persistent problems and recovery after critical illness. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0395
387. Mikkelsen, M. E., & Iwashyna, T. J. (2020). Persistent problems and recovery after critical illness. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0395_update_001
388. Mimica, N., Presečki, P., Jukić, M. K., & Vitezić, D. (2017). Pharmacotherapy in Alzheimer's disease.
389. Mitchell, P. B., Goodwin, G. M., Johnson, G. F., & Hirschfeld, R. M. A. (2008). Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disorders. https://doi.org/10.1111/j.1399-5618.2007.00559.x
390. Modebelu, U., Nargarathan, P. K. M., Marleime, K., & Ramesh, K. (2019). Pharmacologic Therapy for Neonatal Abstinence Syndrome. Journal of Drug Delivery and Therapeutics. https://doi.org/10.22270/jddt.v9i3.2900
391. Molero‐Chamizo, A. (2005). 3,4-metilenodioximetanfetamina (‘éxtasis’): efectos emocionales y cognitivos a largo plazo y depleción serotoninérgica. Revista de Neurología. https://doi.org/10.33588/rn.4102.2004547
392. Moncrieff, J. (2009). A Critique of the Dopamine Hypothesis of Schizophrenia and Psychosis. Harvard Review of Psychiatry. https://doi.org/10.1080/10673220902979896
393. Mondimore, F. M., & Kelly, P. (2011). Borderline Personality Disorder: New Reasons for Hope.
394. Moore, D. P., & Puri, B. K. (2012). Textbook of Clinical Neuropsychiatry and Behavioral Neuroscience 3E.
395. Morales, D. O. (2019). Muerte encefálica en pediatría..
396. Morales, N. N., Gómez‐Revuelta, M., Hernández, B., Zufiaurre, M. L., Itoiz, A. A., Olivares, O. P., González, G. M., Martin, M., Arenaza, J. G., & Arrillaga, A. G. P. (2017). Benzodiazepines abstinence syndrome with psychotic symptoms: Case report. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.568
397. Moreau, J., Scherschlicht, R., Jenck, F., & Martin, J. R. (1995). Chronic mild stress-induced anhedonia model of depression. Behavioural Pharmacology. https://doi.org/10.1097/00008877-199511000-00003
398. Morin, C. (2009). [Sense of personal identity and focal brain lesions].. PubMed. https://doi.org/10.1684/pnv.2009.0156
399. Mula, M., Matteo, P., Basaglia, C., Favaretto, E., & Schwitzer, J. (2013). 2804 – Asenapine after clozapine: is possible?. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)77392-9
400. Munir, S., & Takov, V. (2021). Generalized Anxiety Disorder. StatPearls.
401. Munir, S., Takov, V., & Coletti, V. A. (2021). Generalized Anxiety Disorder (Nursing).
402. Munster, B. C. V., Rooij, S. E. D., & Inouye, S. K. (2016). Delirium, drugs, toxins. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199655946.003.0022
403. Murty, V. L., Baid, G. C., Sharma, S., Singh, S. K., Lath, V., & Jena, P. (2023). Obstructive Sleep Apnea: A Prosthodontist’s Viewpoint. Scholars Journal of Dental Sciences. https://doi.org/10.36347/sjds.2023.v10i05.005
404. Mut, E. A., Pălădoiu, C., & Stănescu, M. (2021). Somatoform and conversion disorders as psychological defences. Journal of Educational Sciences & Psychology. https://doi.org/10.51865/jesp.2021.1.19
405. Mutalib, M. A., Sayed, R., Ansari, N., Safee, R., Rizwan, F., & Parvez, S. E. (2021). Review Study on Sleep and Sleep Deprivation.
406. Muttalib, M. A. (2019). Neuropathic pain treatment between drug therapy and supplement effects. International Journal of Basic & Clinical Pharmacology. https://doi.org/10.18203/2319-2003.ijbcp20194806
407. Méndez, A. V., Silva, P. L. N. D., Gonçalves, L. G. V., Chaves, S. C. D. S., Veiga, R. M., Mendez, A. E. R., Camilo, M. V. L., Mattos, L. C. D. A. N., Filho, M. R. S., Silva, R. D. G. D., Lima, G. F., Ferreira, C. S., & Santos, L. G. D. S. (2023). NEURONAL DAMAGE IN STATE EPILEPTICUS - LITERATURE REVIEW. International Journal of Health Science. https://doi.org/10.22533/at.ed.1593752318094
408. Mırsal, H., Yaluğ, İ., Tan, D., Stern, T. A., Kalyoncu, A., Pektaş, Ö., Erdoğan, G., & Beyazyürek, M. (2005). Brief Report. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.v07n0505
409. Na, I., & Volel, B. A. (2002). [Clinical aspects of "folie du doute"].. PubMed.
410. Naeim, M. (2021). How to control stress caused by COVID-19?. Healthy Aging Research.
411. Nagireddy, R. B. R., & Joshi, D. (2020). Phenytoin induced chorea: an uncommon manifestation. Authorea (Authorea). https://doi.org/10.22541/au.159109589.94248103
412. Naidu, B. M. (2016). Drug Abuse in India. International journal of research in social sciences.
413. Nakata, C., Nara, K., Kinoshita, F., Kikuchi, K., & Asai, M. (2015). [Alcohol withdrawal syndrome showing various progress: A case report].. PubMed.
414. Nakayama, H., Mihara, S., Sakuma, H., Kitamura, D., & Higuchi, S. (2014). SY08-3 * CO-MORBIDITY OF INTERNET ADDICTION. Alcohol and Alcoholism. https://doi.org/10.1093/alcalc/agu052.39
415. Nater, U. M., Miller, A. H., Reeves, W. C., & Raison, C. L. (2010). Chronic Fatigue Syndrome. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0176
416. Nath, P. (2009). Care for addiction through Ayurveda. Indian Journal of Traditional Knowledge.
417. Nava, G. M. (2018). Depression: From Sorrow to Melancholia. Scholarly Journal of Psychology and Behavioral Sciences. https://doi.org/10.32474/sjpbs.2018.01.000106
418. Nelson, J. D., & Chouinard, G. (1999). Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology.. PubMed.
419. Neufeld, K. J., Needham, D. M., Oh, E. S., Wilson, L. M., Nikooie, R., Zhang, A., Koneru, M., Balagani, A., Singu, S., Aldabain, L., & Robinson, K. A. (2019). Antipsychotics for the Prevention and Treatment of Delirium. https://doi.org/10.23970/ahrqepccer219
420. Nguyen, D. C., Timmer, T. K., Davison, B. C., & McGrane, I. R. (2017). Possible <i>Garcinia cambogia</i>-Induced Mania With Psychosis: A Case Report. Journal of Pharmacy Practice. https://doi.org/10.1177/0897190017734728
421. Nicolson, G. L., Nasralla, M. Y., Haier, J., & Nicolson, N. L. (1999). GULF WAR ILLNESSES: ROLE OF CHEMICAL, RADIOLOGICAL AND BIOLOGICAL EXPOSURES.
422. Nikić, P., Zidverc‐Trajkovic, J., Andrić, B., Milinković, M., & Stojimirović, B. (2009). Caffeine-withdrawal headache induced by hemodialysis. The Journal of Headache and Pain. https://doi.org/10.1007/s10194-009-0119-1
423. Norman, E. M., Ferner, R. E., & Rawlins, M. D. (1995). Effects of drugs on behaviour. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198548263.003.0005
424. Novati, A. (2012). Sleep loss, brain vulnerability and psychopathology: experimental studies on the neurobiological consequences of chronic sleep restriction in rats.
425. Odens, M., & Fox, C. H. (1995). Adult sleep apnea syndromes.. PubMed.
426. Oh, S.-H. (2019). 12 - CAN RORSCHACH DIFFERENTIATE BIPOLAR DISORDER FROM DEPRESSIVE DISORDER? : COMPARISON OF RORSCHACH SCORES BETWEEN BIPOAR DEPRESSION AND UNIPOLAR DEPRESSION. https://doi.org/10.26226/morressier.5d1a038757558b317a13f97e
427. Ojimba, C., Isidahome, E. E., Odenigbo, N., Umudi, O. D., & Olayinka, O. (2019). Catatonia in major depressive disorder: diagnostic dilemma. A case report. Journal of Psychology & Clinical Psychiatry. https://doi.org/10.15406/jpcpy.2019.10.00651
428. Oliveira, S., Canha, J., & Pereira, S. P. (2013). 2362 – Is it a prodrome of psychosis? Or is it naanxious disorder? A case report. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)77202-x
429. Olmos-López, A., Ibarra-Aguilar, J., Cornelio-Nieto, J. O., Ocaña-Hernández, L. A., Márquez-Amaya, M. A., Luna-López, N. A., Reséndiz-Aparicio, J. C., & Rodríguez‐Leyva, I. (2019). Clinical guideline: status epilepticus in children and adults. DELETED. https://doi.org/10.24875/rmn.m19000031
430. Olowoyo, P., Oguntoye, O., Akinbote, J. A., & Akinyemi, M. O. R. (2018). Recurrent Prolonged Epileptic Fugue State Misdiagnosed as Psychosis? Tale of a Middle-Aged Female Nigerian African. International Journal of Innovative Research in Medical Science. https://doi.org/10.23958/ijirms/vol02-i09/04
431. Otsuka, K., Kato, S., Abe, T., SUGIYAMA, H., Watanabe, Y., Kobayashi, T., & Okajima, Y. (2002). [Classification of long-term clinical course of 'atypical psychosis': a 20-year follow-up study at a medical school hospital].. PubMed.
432. Ozbal, F. S., & Sinha, B. (2025). Hypomanic Switch Induced by Lurasidone: A Case Report. BJPsych Open. https://doi.org/10.1192/bjo.2025.10754
433. Padmos, R. C. (2009). Inflammatory Monocytes in Bipolar Disorder and Related Endocrine Autoimmune Diseases.
434. Page, R. D. (1983). Cerebral dysfunction associated with alcohol consumption.. PubMed.
435. Pagel, J., Pandi‐Perumal, S. R., & Monti, J. M. (2018). Treating insomnia with medications. Sleep Science and Practice. https://doi.org/10.1186/s41606-018-0025-z
436. Pandya, D., Shinkar, D. M., & Saudagar, R. B. (2016). Kleptomania: An overview. Asian Journal of Pharmacy and Technology. https://doi.org/10.5958/2231-5713.2016.00017.9
437. Paradela, E. M. P. (2011). Depressão em idosos. Revista Hospital Universitário Pedro Ernesto (TÍTULO NÃO-CORRENTE). https://doi.org/10.12957/rhupe.2011.8850
438. Paredes, D. F. D., Farfán, J. C. P., Orellana, J. M. F., & Legarda, A. A. B. (2019). Trastorno disfórico premenstrual. RECIAMUC. https://doi.org/10.26820/reciamuc/3.(1).enero.2019.199-217
439. Parolaro, D., Viganò, D., & Rubino, T. (2005). Endocannabinoids and Drug Dependence. Current Drug Targets - CNS & Neurological Disorders. https://doi.org/10.2174/156800705774933014
440. Parrott, A. C. (2001). Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Human Psychopharmacology Clinical and Experimental. https://doi.org/10.1002/hup.351
441. Patricia, G. C. C., AAngela, G.-M., & Marina, R.-A. (2017). Diagnostic and therapeutical challenges of late-onset psychosis.. Journal of Psychology and Cognition. https://doi.org/10.35841/psychology-cognition.2.4.218-220
442. Patti, L., & Gupta, M. (2019). Change In Mental Status. StatPearls.
443. Paulin, L. F. R. D. S., Reis, E. F. D., & Rodrigues, E. P. (2008). Síndrome de descontinuação dos antidepressivos.
444. Peköz, M. T., Gök, D. K., Bozdemir, H., & Aslan, K. (2017). Diagnostic Criteria of Parasomnias and Other Paroxysmal Events in Sleep. Turkish Journal of Family Medicine & Primary Care. https://doi.org/10.21763/tjfmpc.318059
445. Peretti, C.-S., Ferreri, F., & Crucis, B. (2009). Troubles cognitifs dans la dépression. La Lettre du psychiatre.
446. Pergolizzi, J. V., Coluzzi, F., Varrassi, G., Mariano, D. J., LeQuang, J. A., Bisney, J., & Magnusson, P. (2019). Red wine triggers may lead to better understanding of migraine headache: a narrative review. Journal of Wine Research. https://doi.org/10.1080/09571264.2019.1573360
447. Petrenko, A. B., Takamatsu, M., & Baba, H. (2012). Should We Use Psychostimulant Drugs to Boost the Emergence from General Anesthesia?. Anesthesiology. https://doi.org/10.1097/aln.0b013e318272d898
448. Picetti, R., Schlussman, S. D., Zhou, Y., Ray, B., Ducat, E., Yuferov, V., & Kreek, M. J. (2013). Addictions and Stress: Clues for Cocaine Pharmacotherapies. Current Pharmaceutical Design. https://doi.org/10.2174/13816128113199990610
449. Pickard, H. (2011). What Is Personality Disorder?. Philosophy, psychiatry & psychology. https://doi.org/10.1353/ppp.2011.0040
450. Pigato, G., Roiter, B., Cecchin, D., Morbelli, S., Tenconi, E., Minelli, A., & Bortolomasi, M. (2016). Electroconvulsive Therapy in a Patient With Chronic Catatonia. Journal of Ect. https://doi.org/10.1097/yct.0000000000000333
451. Pikirenia, U., Fedotov, I., Tuchina, O., & Kapytau, A. U. (2017). Cognitive impairment due to alcohol abuse: current status of research. Vestnik of Saint Petersburg University Medicine. https://doi.org/10.21638/11701/spbu11.2017.306
452. Plotkin, K. E. (2007). Insomnia Caused by Medical Disorders. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-042-7_15
453. Poirier, M. F., & Ginestet, D. (1995). [Drugs diverted from reaching drug addicts].. PubMed.
454. Popescu, D., Popescu, G., Lupu, G., Panus, V., Neagu-Sadoveanu, S., & Buda, O. (2010). Drugs effects on the central nervous system. Forensic implications. Romanian Journal of Legal Medicine. https://doi.org/10.4323/rjlm.2010.231
455. Porcelli, P., Laera, D., Mastrangelo, D., & Masi, A. D. (2012). Prevalence of Allostatic Overload Syndrome in Patients with Chronic Cardiovascular Disease. Psychotherapy and Psychosomatics. https://doi.org/10.1159/000341179
456. Praag, H. M. V. (1998). Anxiety and increased aggression as pacemakers of depression. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/j.1600-0447.1998.tb05971.x
457. Presečki, P., Filipčić, I., Arbanas, G., & Mimica, N. (2014). Neurocognitive disorders in DSM-5.
458. Prommer, E. (2006). Prevalence and characterization of the insomnia syndrome in an outpatient oncology clinic. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.24.18_suppl.18612
459. Purnama, D. M. W., & Rahmanisa, S. (2016). Pengaruh Musik Klasik dalam Mengurangi Tingkat Kekambuhan Penderita Skizofrenia di Rumah. Jurnal Majority.
460. Pysden, K. (2015). Alternating hemiplegia of childhood. Journal of Pediatric Neurology. https://doi.org/10.3233/jpn-2010-0337
461. Pälvimäki, E.-P., Siironen, J., Pohjola, J., & Hernesniemi, J. (2011). [Brain concussion].. PubMed.
462. Pérez-Romero, J. L., Hernández‐Fernández, F., Moratalla, A. B. P., Ayo‐Martín, Ó., & Rubio, M. E. O. (2010). Síncopes de Repetición como presentación de Encefalopatía de Wernicke-Korsakov. Revista Clínica de Medicina de Familia. https://doi.org/10.4321/s1699-695x2010000200017
463. Pétursson, H. (1994). The benzodiazepine withdrawal syndrome. Addiction. https://doi.org/10.1111/j.1360-0443.1994.tb03743.x
464. Płytycz, B., & Seljelid, R. (2002). Stress and immunity: minireview.. PubMed.
465. Qureshi, M. A., & Wasti, S. A. (2014). Lay-off Survivor Sickness Syndrome (Investigating the Lasting Impact on Performance of Survivors in the Context of Age and Gender in Private Sector Organizations of Pakistan). International Journal of Human Resource Studies. https://doi.org/10.5296/ijhrs.v4i3.6078
466. Rakofsky, J. J., & Dunlop, B. W. (2014). Treating Bipolar Mania in the Outpatient Setting: Enlist the Help of Family, Employ Evidence-Based Pharmacologic and Psychotherapeutic Strategies. Current psychiatry.
467. Rastegar, D. A., & Fingerhood, M. (2015). Cocaine, Methamphetamine, and Other Stimulants. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0008
468. Rastegar, D. A., & Fingerhood, M. (2015). Hallucinogens and Dissociatives. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0009
469. Rd, G. (1996). Behavioral factors in the management of back pain.. PubMed.
470. Reddy, M. S. (2014). Irritability as a Criterion in Diagnosis of Child and Adolescent Bipolar Disorder: Thorny Road Ahead. Indian Journal of Psychological Medicine. https://doi.org/10.4103/0253-7176.130954
471. Reichenberg, L. W., & Seligman, L. (2016). Bipolar and Related Disorders. https://doi.org/10.1002/9781394259465.ch4
472. Reichenberg, L. W., & Seligman, L. (2016). Dissociative Disorders. https://doi.org/10.1002/9781394259465.ch9
473. Reichenberg, L. W., & Seligman, L. (2016). Sleep‐Wake Disorders. https://doi.org/10.1002/9781394259465.ch13
474. Reid, W. H., Balis, G. U., & Sutton, B. (1997). The treatment of psychiatric disorders : revised for DSM-IV.
475. Reinares, M., Martínez‐Arán, A., & Vieta, E. (2019). Psychoeducation for Patients and Family Members. Cambridge University Press eBooks. https://doi.org/10.1017/9781108589802.004
476. Renault, P. F., Hoofnagle, J. H., Park, Y., Mullen, K. D., Peters, M. G., Jones, D. B., Rustgi, V. K., & Jones, E. A. (1987). Psychiatric Complications of Long-term Interferon Alfa Therapy. Archives of Internal Medicine. https://doi.org/10.1001/archinte.1987.00370090055011
477. Reuber, M., Schachter, S. C., Elger, C. E., & Altrup, U. (2009). Conditions Associated With Epilepsy. https://doi.org/10.1093/oso/9780195379532.003.0005
478. Reynolds, E., & Wilson, J. V. K. (2014). Neurology and psychiatry in Babylon. Brain. https://doi.org/10.1093/brain/awu192
479. Rhoney, D. H., & Varelas, P. N. (2009). Drug-Induced Seizures in Critically Ill Patients. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-532-3_13
480. Ritz, L., Pitel, A., Vabret, F., Eustache, F., & Beaunieux, H. (2012). Alcoolodépendance : atteintes neuropsychologiques et diagnostics différentiels. Revue de neuropsychologie. https://doi.org/10.1684/nrp.2012.0227
481. Rivas-Vazquez, R. A., Carrazana, E., Rey, G., & Wheeler, S. D. (2000). SELECTIVE SEROTONIN REUPTAKE INHIBITOR DISCONTINUATION SYNDROME: THREE CASES PRESENTING TO A NEUROLOGIC PRACTICE. The Neurologist. https://doi.org/10.1097/00127893-200006060-00005
482. Riverón-Carralero, W. J., Rondón-Vázquez, A. F., & Gómez, O. G. (2020). Coma hipopotasémico: a propósito de un caso. Universidad Médica Pinareña.
483. Roberts, A. J., & Koob, G. F. (1997). The neurobiology of addiction: an overview.. PubMed.
484. Roberts, A. R., & Yeager, K. R. (2009). Indicators of a Crisis-Prone Person. https://doi.org/10.1093/oso/9780195382907.003.0004
485. Roberts, A. R., & Yeager, K. R. (2009). Psychophysiological Reactions to a Crisis. https://doi.org/10.1093/oso/9780195382907.003.0007
486. Roberts, A. R., & Yeager, K. R. (2009). Stress Symptomatology and the General Adaptation Syndrome. https://doi.org/10.1093/oso/9780195382907.003.0008
487. Robinson, C. P., & Hocker, S. E. (2019). Status Epilepticus. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190862923.003.0098
488. Robinson, T. E. (2014). Sensitization to Drugs.
489. Rodriguez, C. P., Dodds, T., & Suzuki, J. (2017). Addiction. Pain Medicine. https://doi.org/10.1007/978-3-319-43133-8_33
490. Rolland, B., Simon, N., & Franchitto, N. (2018). Safety Challenges of Using High Dose Baclofen for Alcohol Use Disorder: A Focused Review. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2018.00367
491. Ronad, S. V., Patail, C. S., Gondbal, S. H., TC, K., Ronad, M., Pankaja, T., Badesgol, R., & Singhal, P. K. J. (2019). Professionals in metro cities suffer from anxiety disorder. Nursing & Care Open Access Journal. https://doi.org/10.15406/ncoaj.2019.06.00198
492. Rosebush, P. I., & Mazurek, M. F. (1996). Catatonia After Benzodiazepine Withdrawal. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199608000-00007
493. Roth, T., Krystal, A. D., & Lieberman, J. A. (2007). Long-term issues in the treatment of sleep disorders.. CNS Spectrums.
494. Roy‐Byrne, P., Lydiard, R. B., & Ballenger, J. C. (1988). Recent Advances in the Psychopharmacological Treatment of Anxiety Disorders. Psychiatric Services. https://doi.org/10.1176/ps.39.11.1157
495. Rucci, J. M., & Feinstein, R. E. (2014). Neurocognitive Disorders and Mental Disorders Due to Another Medical Condition. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199326075.003.0005
496. Ruiz, C. B., Torralbo, M. B., Garcia, R. R., Llobet, A. H., Fernández, I. A., Nielsen, N. P., Landeo, A. R., Ramírez, M. M., Fuentes, D. G., Soler, M. A., & Cañete, J. (2020). Psicosis dual y cariprazina. Caso clínico. LIBRO COMUNICACIONES. https://doi.org/10.17579/sepd2020p141
497. Ruiz‐Rizzo, A. L., & Restrepo, F. L. (2008). Memoria explícita en el trastorno depresivo mayor. IATREIA. https://doi.org/10.17533/udea.iatreia.4479
498. Ruoff, C., & Rye, D. B. (2016). The ICSD-3 and DSM-5 guidelines for diagnosing narcolepsy: clinical relevance and practicality. Current Medical Research and Opinion. https://doi.org/10.1080/03007995.2016.1208643
499. Ryan, M., & Slevin, J. T. (2007). Restless Legs Syndrome. Journal of Pharmacy Practice. https://doi.org/10.1177/0897190007310914
500. Saeed, S. A. (2009). Social Anxiety Disorder: An Update on Evidence-Based Treatment Options.
501. Salani, D., Albuja, L. D., & Zdanowicz, M. M. (2018). The Explosion of a New Designer Drug, Flakka. Journal of Addictions Nursing. https://doi.org/10.1097/jan.0000000000000252
502. Salaspuro, M. (2009). [Intoxicated patient at the emergency department and referral to treatment].. PubMed.
503. Sandi, C. (2013). Stress and cognition. Wiley Interdisciplinary Reviews Cognitive Science. https://doi.org/10.1002/wcs.1222
504. Sarris, J., O’Neil, A., Coulson, C., Schweitzer, I., & Berk, M. (2014). Lifestyle medicine for depression. BMC Psychiatry. https://doi.org/10.1186/1471-244x-14-107
505. Sass, L. A. (2003). “Negative Symptoms,” Commonsense, and Cultural Disembedding in the Modern Age. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511616297.015
506. Sazonov, S. (2014). EPA-0651 – The complexity of psychopathological symptom as a possible indication of mental disease's etiology. European Psychiatry. https://doi.org/10.1016/s0924-9338(14)78023-x
507. Scala, M., Fanelli, G., Ronchi, D. D., Serretti, A., & Fabbri, C. (2023). Clinical specificity profile for novel rapid acting antidepressant drugs. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0000000000000488
508. Schapira, A. H., & Olanow, C. W. (2009). Drug selection and timing of initiation of treatment in early Parkinson's disease. Annals of Neurology. https://doi.org/10.1002/ana.21460
509. Scheer, V., & Knechtle, B. (2020). Exercise associated hyponatremia in endurance sports: a review with practical recommendations. Archivos de medicina del deporte: revista de la Federación Española de Medicina del Deporte y de la Confederación Iberoamericana de Medicina del Deporte.
510. Schildkrout, B. (2014). Delirium. https://doi.org/10.1002/9781394260447.ch2
511. Schildkrout, B. (2014). Disease #54: Premenstrual Dysphoric Disorder and Premenstrual Syndrome. https://doi.org/10.1002/9781394260447.ch82
512. Schildkrout, B. (2014). Disease #57: <scp>REM</scp> Sleep Behavior Disorder. https://doi.org/10.1002/9781394260447.ch85
513. Schildkrout, B. (2014). Vegetative Symptoms. https://doi.org/10.1002/9781394260447.ch23
514. Schott, J. M. (2020). Alzheimer’s disease and other dementias. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0574
515. Schutte, M., Mathias, B., & Hopf, G. (1988). [Adverse effects of antihistaminics].. PubMed.
516. Schwerthöffer, D., Fatke, B., & Förstl, H. (2020). Dilemmasituation: Nächtlicher Unruhezustand beim älteren Patienten.
517. Scotton, W. J., Hill, L. J., Williams, A., & Barnes, N. M. (2019). Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions. International Journal of Tryptophan Research. https://doi.org/10.1177/1178646919873925
518. Sekhon, S., Patel, J., & Sapra, A. (2019). Late Onset Depression. StatPearls.
519. Sengupta, R., Roy, S., & Bhattacharya, M. (2019). STUDY OF GENE-ENVIRONMENT CAUSES OF MAJOR DEPRESSIVE DISORDER TO STATISTICALLY DEFINE THE MOST COMMON CAUSE BEHIND IT.. International Journal of Advanced Research. https://doi.org/10.21474/ijar01/8804
520. Sepede, G., Iorio, G. D., Sarchione, F., Fiori, F., & Giannantonio, M. D. (2017). Bupropion Augmentation in a Case of Compulsive Buying Disorder. Clinical Neuropharmacology. https://doi.org/10.1097/wnf.0000000000000232
521. Serageldin, M., Hikmet, W., & Alani, S. (2019). Insomnia is a Prodromal Symptom for Psychosis. Journal of the Bahrain Medical Society. https://doi.org/10.26715/jbms.31_31012019
522. Serecigni, J. G., Segura, L., Gonzalvo, B., Iglesias, L., & Roncero, C. (2001). Neuroimagen y alteraciones del funcionamiento cerebral, asociadas al consumo de cocaína. Adicciones. https://doi.org/10.20882/adicciones.556
523. Sevarino, K. A., & Shelby, B. C. (2015). Stimulant Use Disorders. Psychiatry. https://doi.org/10.1002/9781118753378.ch80
524. Sewart, A. R., & Craske, M. G. (2018). Panic Disorder and Agoraphobia. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190492243.003.0013
525. Sh.H., S., L.A., T., N.I., K., V.K., A., & Nurkhodjaev, S. (2020). Diagnostics of Dysthymic Disorders and Therapy of Patients with Opium Addiction with AnxietyDepressive Variant of Post-Withdrawal Syndrome. International Journal of Current Research and Review. https://doi.org/10.31782/ijcrr.2020.122320
526. Shah, J. S., Owen-Smith, O., Coley, S. M., & Rangasami, J. (2000). A survey of peripheral nerve stimulator (PNS) use. European Journal of Anaesthesiology. https://doi.org/10.1046/j.1365-2346.2000.00586.x
527. Shah, J. S., Owen-Smith, O., Coley, S. M., & Rangasami, J. (2000). A survey of peripheral nerve stimulator (PNS) use. European Journal of Anaesthesiology. https://doi.org/10.1097/00003643-200004000-00012
528. Shams, J., Rahmani, B., Asefi, F., & Daneshfar, S. (2010). CATATONIA DEVELOPMENT IN A SCHIZOAFFECTIVE PATIENT FOLLOWING ELECTROCONVULSIVE THERAPY: CASE REPORT.
529. Sheets, E. S., & Brosse, A. L. (2010). Major Depressive Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0522
530. Shirley, E. A., Hudspeth, L. J., & Maynard, J. R. (2018). Managing Sports-related Concussions From Time of Injury Through Return to Play. Journal of the American Academy of Orthopaedic Surgeons. https://doi.org/10.5435/jaaos-d-16-00684
531. Shou-zh, W. (2008). Drug Psychosis by Antipsychotic Drugs:Report of 40 Cases. Zhongguo quanke yixue.
532. Silva, L. I. F. D., Souza, L. M., Gonzales, M. F., & Jurado, S. R. (2015). SLEEP DISORDERS IN CHILDHOOD. Simpósio Internacional de Neurociências da Grande Dourados.
533. Sinha, S., Moss, A. J., & Calkins, H. (2007). The etiology of sudden death. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544828.014
534. Smith, S. S. (2019). Insomnia and Clinical Sleep Disturbance in Later Life. Oxford Research Encyclopedia of Psychology. https://doi.org/10.1093/acrefore/9780190236557.013.419
535. Snaith, P. (1994). Anxiety Control Training. Advances in Psychiatric Treatment. https://doi.org/10.1192/apt.1.2.57
536. Snyder, S. H. (2019). CNS Stimulants And Hallucinogens. CRC Press eBooks. https://doi.org/10.1201/9780429260629-8
537. Solimini, R., Rotolo, M. C., Pichini, S., & Pacifici, R. (2017). Neurological Disorders in Medical Use of Cannabis: An Update. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/1871527316666170413105421
538. Sorvaniemi, M. (2009). When an antidepressant helps too much. Duodecim lääketieteellinen aikakauskirja.
539. Sousa, C. D. (2007). Oral Communication 4, Monday Sept. 24th 5.00 pm-6.00 pm; Room: Lecture Hall 1: Attention, emotion and Behavior--Part 2. Alcohol and Alcoholism. https://doi.org/10.1093/alcalc/agm116
540. Soysal, P., & Işık, A. T. (2014). Hypoactive Delirium Caused by Pulmonary Embolus in an Elderly Adult. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.12720
541. Spanagel, R., Tran, B. X., Reyes‐Gibby, C. C., DeBeck, K., Ibrahim, F., & Bonevski, B. (2016). Advances in Drug Addiction.
542. Spencer, T., Biederman, J., Wilens, T. E., & Faraone, S. V. (2002). Novel treatments for attention-deficit/hyperactivity disorder in children.. PubMed.
543. Sriramoju, M., Keerthi, V. P., Alumdri, D. B., & Akula, S. (2014). Evaluation of antidepressant activity of ethanolic and aqueous extract of Solanum tuberosum peel. Journal of Comprehensive Pharmacy. https://doi.org/10.37483/jcp.2014.1503
544. Stahl, S. M. (2000). Blue Genes and the Mechanism of Action of Antidepressants. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v61n0302
545. Steffens, D. C., Blazer, D. G., & Beyer, J. L. (2013). Mood Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781615370016.mt05
546. Stewart, J. (2003). Stress and Relapse to Drug Seeking: Studies in Laboratory Animals Shed Light on Mechanisms and Sources of Long‐Term Vulnerability. American Journal on Addictions. https://doi.org/10.1111/j.1521-0391.2003.tb00535.x
547. Stewart, S. M. (2013). Depression. The Encyclopedia of Cross‐Cultural Psychology. https://doi.org/10.1002/9781118339893.wbeccp158
548. Stoller, K. B. (2015). Psychiatric Co-occurring Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0015
549. Stone, J., Carson, A., & Sharpe, M. (2005). Functional symptoms in neurology: management. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2004.061663
550. Strain, J. J., Klipstein, K., & Newcorn, J. H. (2008). Adjustment Disorders. Psychiatry. https://doi.org/10.1002/9780470515167.ch81
551. Strupp, M., López‐Escámez, J. A., Kim, J., Straumann, D., Jen, J. C., Carey, J. P., Bisdorff, A., & Brandt, T. (2017). Vestibular paroxysmia: Diagnostic criteria. Journal of Vestibular Research. https://doi.org/10.3233/ves-160589
552. Sugiyama, H., & Kanba, S. (2001). [Symptomatology and diagnosis of depression].. PubMed.
553. Suhl, J. (2007). The Neuropharmacology of Sleep Disorders: Better Sleeping Through Chemistry?. Journal of Pharmacy Practice. https://doi.org/10.1177/0897190007305149
554. Summers, C. B. (2007). Cognitive-Behavior Group Therapy in Residential Treatment. https://doi.org/10.4324/9780203941157-16
555. Sung, H. C., & Chang, A. B. (2010). The effectiveness of preferred or familiar music listening on behavioural and psychological symptoms of institutionalised older adults with dementia: a systematic review. JBI Library of Systematic Reviews. https://doi.org/10.11124/jbisrir-2010-726
556. Sung, H. C., & Chang, A. B. (2010). The effectiveness of preferred or familiar music listening on behavioural and psychological symptoms of institutionalised older adults with dementia: a systematic review. The JBI Database of Systematic Reviews and Implementation Reports. https://doi.org/10.11124/01938924-201008341-00020
557. Surova, G., Ulke, C., Schmidt, F., Hensch, T., Sander, C., & Hegerl, U. (2020). Fatigue and brain arousal in patients with major depressive disorder. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-020-01216-w
558. Sussman, S. (2025). Vulnerability to addictive behaviors: the Associational Memory‐Appetitive Systems Relations Model. World Psychiatry. https://doi.org/10.1002/wps.21283
559. Swann, A. C. (2009). Pharmacologic Mood Destabilization: <i>Case Vignettes</i>. CNS Spectrums. https://doi.org/10.1017/s1092852900003898
560. Söderpalm, B. (2002). Anticonvulsants: aspects of their mechanisms of action. European Journal of Pain. https://doi.org/10.1053/eujp.2001.0315
561. Tacn, A. (2012). PTSD in the Context of Malignant Disease. InTech eBooks. https://doi.org/10.5772/27424
562. Takahashi, Y. (2007). 1. Neuromuscular Disorders Caused by Adverse Effects of Antiepileptic. Nihon Naika Gakkai Zasshi. https://doi.org/10.2169/naika.96.1608
563. Takács, R., Milan, F., Ungvári, G. S., Faludi, G., & Gazdag, G. (2016). Catatonia in disulfiram intoxication - a case report and a brief overview of the literature.. PubMed.
564. Tan, B. L. W., & Gudi, A. (2021). A rare case: Mania associated with pazopanib. Proceedings of Singapore Healthcare. https://doi.org/10.1177/20101058211023778
565. Tanaka, M., Tajima, S., Mizuno, K., Ishii, A., Konishi, Y., Miike, T., & Watanabe, Y. (2015). Frontier studies on fatigue, autonomic nerve dysfunction, and sleep-rhythm disorder. The Journal of Physiological Sciences. https://doi.org/10.1007/s12576-015-0399-y
566. Tang‐Wai, D. F., Josephs, K. A., & Petersen, R. C. (2005). Alzheimer's disease: overview. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544873.029
567. Taylor, M. E., & Whitney, J. (2021). Impaired Cognition and Falls. Cambridge University Press eBooks. https://doi.org/10.1017/9781108594455.009
568. Teja, N., Gummadi, O. D., Devi, B. V., & Pavani, N. (2020). Evaluation of Depressant Activity on Mansoa alliacea on Rats. Acta Scientific Pharmaceutical Sciences. https://doi.org/10.31080/asps.2020.04.0617
569. Terman, M., & Terman, J. S. (2013). Chronotherapeutics. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781139175869.026
570. Terman, M., Lewy, A. J., Dijk, D., Boulos, Z., Eastman, C. I., & Campbell, S. S. (1995). Light Treatment for Sleep Disorders: Consensus Report. Journal of Biological Rhythms. https://doi.org/10.1177/074873049501000206
571. Thakur, A., Choudhary, D., Kumar, B., & Chaudhary, A. (2021). A Review on Post-traumatic Stress Disorder (PTSD): Symptoms, Therapies and Recent Case Studies. Current Molecular Pharmacology. https://doi.org/10.2174/1874467214666210525160944
572. Thase, M. E. (2005). Bipolar Depression: Issues in Diagnosis and Treatment. Harvard Review of Psychiatry. https://doi.org/10.1080/10673220500326425
573. Thompson, A., & Weber, A. (2021). Alcohol and Drug Withdrawal Syndromes and Their Clinical Management. DeckerMed Family Medicine. https://doi.org/10.2310/fm.13043
574. Thompson, A., & Weber, A. (2021). Alcohol and Drug Withdrawal Syndromes and Their Clinical Management. https://doi.org/10.2310/cannabis.13043
575. Thompson, A., & Weber, A. (2021). Alcohol and Drug Withdrawal Syndromes and Their Clinical Management. https://doi.org/10.2310/psych.13043
576. Tiglao, S. M., Meisenheimer, E. S., & Oh, R. (2021). Alcohol Withdrawal Syndrome: Outpatient Management.. American family physician.
577. Tobin, D. L., Molteni, A., & Elin, M. R. (1995). Early trauma, dissociation, and late onset in the eating disorders. International Journal of Eating Disorders. https://doi.org/10.1002/1098-108x(199504)17:3<305::aid-eat2260170312>3.0.co;2-f
578. Tondo, L., & Baldessarini, R. J. (2020). Discontinuing psychotropic drug treatment. BJPsych Open. https://doi.org/10.1192/bjo.2020.6
579. Tong, G., Groom, K. N., Ward, L., & Naeem, M. Y. (2021). “This Is Not the Original Timeline”: A Case Report of an Extended Dissociative Episode in a Healthy Young Male Accompanied with Severe Decline in Mental State. Case Reports in Psychiatry. https://doi.org/10.1155/2021/6619579
580. Tonkin, A., & Frewin, D. B. (2013). Drugs, chemicals, and toxins that alter autonomic function. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198566342.003.0073
581. Toom, K., Braschinsky, M., Obermann, M., & Katsarava, Z. (2020). Secondary headache attributed to exposure to or overuse of a substance. Cephalalgia. https://doi.org/10.1177/0333102420942238
582. Tp, P., & Ms, D. (1987). [The current understanding of so-called exceptional states in the forensic psychiatry clinic].. PubMed.
583. Trenité, D. K. (2012). Provoked and reflex seizures: Surprising or common?. Epilepsia. https://doi.org/10.1111/j.1528-1167.2012.03620.x
584. Trill, M. D. (2012). Psychological aspects of depression in cancer patients: an update. Annals of Oncology. https://doi.org/10.1093/annonc/mds350
585. Trivedi, K., Kataria, L., & Patel, D. (2020). A COMPARATIVE STUDY EVALUATING THE DEPRESSIVE SYMPTOMS AND FUNCTIONAL OUTCOME IN PATIENTS TREATED WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS V/S SEROTONIN–NOREPINEPHRINE REUPTAKE INHIBITORS AS ANTIDEPRESSANT AGENTS IN MAJOR DEPRESSIVE DISORDER.
586. Trivedi, M. S., Hershman, D. L., & Crew, K. D. (2015). Management of Chemotherapy-Induced Peripheral Neuropathy. American Journal of Hematology / Oncology®.
587. Tso, I. F., Chun, J., & Deldin, P. J. (2010). Schizoaffective Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0818
588. Tu, K.-Y., & Lin, P. (2014). Hypomania Soon After Shifting From Paroxetine to Agomelatine in a Middle-Aged Woman With Depression. Clinical Neuropharmacology. https://doi.org/10.1097/wnf.0000000000000030
589. Tudor, L., Perković, M. N., Erjavec, G. N., Konjevod, M., Štrac, D. Š., Uzun, S., Kozumplik, O., & Pivac, N. (2017). The association between platelet MAO-B activity and specific symptoms in PTSD.
590. Uddin, M. S., Sufian, M. A., Kabir, M. T., Hossain, M. F., Nasrullah, M., Islam, I., Mamun, A. A., Islam, M. T., & Khanum, S. (2017). Amphetamines: Potent Recreational Drug of Abuse. Journal of Addiction Research & Therapy. https://doi.org/10.4172/2155-6105.1000330
591. Upadhyay, S., Elmatite, W., Taqi, S., Jagia, M., & Mallick, P. (2011). Dexmedetomidine infusion to facilitate opioid detoxification and withdrawal in a patient with chronic opioid abuse. Indian Journal of Palliative Care. https://doi.org/10.4103/0973-1075.92353
592. Vanderschuren, L. J. M. J. (2008). Neurobehavioral Mechanisms of Compulsive Drug Seeking. https://doi.org/10.1093/oso/9780195300550.003.0009
593. Varı̀, M. R., Pichini, S., Giorgetti, R., & Busardò, F. P. (2018). New psychoactive substances—Synthetic stimulants. Wiley Interdisciplinary Reviews Forensic Science. https://doi.org/10.1002/wfs2.1197
594. Velasco-Rey, M. C., Sánchez-Muñoz, M., Lopez, M., Trujillo-Borrego, A., & Sánchez-Bonome, L. (2012). Psychotic depression induced by Obstructive Sleep Apnoea Syndrome (OSAS): a case reported.. PubMed.
595. Vendruscolo, L. F., & Koob, G. F. (2019). Alcohol Dependence Conceptualized as a Stress Disorder. https://doi.org/10.1093/oxfordhb/9780190681777.013.9
596. Vidić, M. (2018). Psihološki aspekti ovisnosti o psihoaktivnim tvarima.
597. Vivanco, E. F., Gómez, C. P., & Martínez, R. G. (2006). Patología orgànica por drogas de síntesis. Adicciones.
598. Vlaminck, J., Vliet, I. M. V., & Zitman, F. (2005). [Withdrawal symptoms of antidepressants].. PubMed.
599. Walker, M. C. (2020). Narcolepsy. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0576
600. Walterscheid, B., Eshak, N., & Nugent, K. (2021). Altered mental status in a patient with psychiatric history: Medication noncompliance or medical etiology?. Journal of Investigative Medicine.
601. Wand, G. S. (2008). The influence of stress on the transition from drug use to addiction.. PubMed.
602. Wang, S. (2001). Analysis on the 30 Cases of the Mental Barriers Caused by Taking Some Anti-psychosis Drugs. Journal of Inner Mongolia University for Nationalities.
603. Watanabe, H., & Terao, T. (1997). A Case of Depression Manifesting Incessant Pacing and Wandering following Discontinuation of Antipsychotic Drugs due to Neuroleptic Malignant Syndrome: A Possible Involvement of Withdrawal Akathisia. Journal of UOEH. https://doi.org/10.7888/juoeh.19.29
604. Weaver, M. (2018). Substance-Related Disorders. American Psychiatric Association Publishing eBooks. https://doi.org/10.1176/appi.books.9781615371990.jl16
605. Weibel, S., Mallaret, M., Bennouna-Greene, M., & Bertschy, G. (2013). 2824 – Acute psychosis and buprenorphine withdrawal: abrupt vs. progressive could make a difference. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)77409-1
606. Weisholtz, D. S., & Dworetzky, B. A. (2014). Epilepsy and Psychosis.
607. Weiss, B., Clarkson, T. W., & Simon, W. (2002). Silent latency periods in methylmercury poisoning and in neurodegenerative disease.. Environmental Health Perspectives. https://doi.org/10.1289/ehp.02110s5851
608. Werdenich, W., & Padlesak, S. (2000). &lt;F63&gt; Abnorme Gewohnheiten und Störungen der Impulskontrolle. https://doi.org/10.1007/978-3-7091-3768-0_25
609. Werner, F. M., & Coveñas, R. (2016). Additional Antidepressant Pharmacotherapies According to a Neural Network. Brain Disorders & Therapy. https://doi.org/10.4172/2168-975x.1000203
610. Wiglusz, M. S., Cubała, W. J., Nowak, P. M., Jakuszkowiak‐Wojten, K., Landowski, J., & Krysta, K. (2013). Sibutramine-associated psychotic symptoms and zolpidem-induced complex behaviours: implications for patient safety.. PubMed.
611. Wilson, D. S., & Nutt, P. D. J. (2013). Insomnia. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199674558.003.0003
612. Winstock, A., & Schifano, F. (2012). Disorders relating to the use of ecstasy and other ‘party drugs’. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0066
613. Winston, A. P., Hardwick, E., & Jaberi, N. (2005). Neuropsychiatric effects of caffeine. Advances in Psychiatric Treatment. https://doi.org/10.1192/apt.11.6.432
614. Winters, K. C., & Ingwalson, A. (2022). Internalizing and Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190678487.003.0006
615. Winters, K. C., & Ingwalson, A. (2022). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190678487.003.0005
616. Wissow, L. S. (2021). Anxiety and Trauma-Related Distress. Pediatric Care Online. https://doi.org/10.1542/aap.ppcqr.396464
617. Wiśniewski, M., Anand, J. S., Chodorowski, Z., & Kosińska-Tomczyk, H. (2007). [Tiagabine overdose--report of two cases].. PubMed.
618. Wolfe, R. (1997). Antidepressant withdrawal reactions.. PubMed.
619. Woo, C. H., & Kim, S. (2014). Effectiveness of the Military Mental Health Promotion Program. Journal of Korean Academy of Nursing. https://doi.org/10.4040/jkan.2014.44.6.717
620. Wood, S., Sage, J. R., Shuman, T., & Anagnostaras, S. (2013). Psychostimulants and Cognition: A Continuum of Behavioral and Cognitive Activation. Pharmacological Reviews. https://doi.org/10.1124/pr.112.007054
621. Wright, S. L. (2020). Benzodiazepine Withdrawal. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197517277.003.0008
622. Wyatt, J. P., Illingworth, R. N., Graham, C. A., Hogg, K., Clancy, M., & Robertson, C. E. (2012). Environmental emergencies. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199589562.003.0006
623. Yarlagadda, A. R., Brown, A. B., & Clayton, A. H. (2007). Onset of Obstructive Sleep Apnea After Initiation of Psychotropic Agents. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0611h
624. Yee, B. J., Liu, P. Y., Phillips, C. L., & Grunstein, R. R. (2013). Neuroendocrine aspects of sleep apnea. CRC Press eBooks. https://doi.org/10.3109/9781420020885-16
625. Yehuda, R., Lehrner, A., & Pratchett, L. C. (2016). Trauma‐ and Stressor‐Related Disorders. https://doi.org/10.1002/9781118654231.ch13
626. Yeşil, B., & Elbozan, H. B. (2016). Gabapentin withdrawal in a depressed patient: A case report. Anatolian Journal of Psychiatry. https://doi.org/10.5455/apd.223708
627. Young, W. B., Packard, R. C., & Katsarava, Z. (2007). Headaches Associated with Head Trauma. https://doi.org/10.1093/oso/9780195326567.003.0016
628. Yui, K. (2015). EDITORIAL (Thematic Issue: New Targets of Medical Treatment in Psychiatric Disorders). Current Neuropharmacology. https://doi.org/10.2174/1570159x1306151126144423
629. Yui, K., Kajii, Y., & Nishikawa, T. (2006). Neurobiological and Molecular Bases of Methamphetamine-Induced Behavioral Sensitization and Spontaneous Recurrence of Methamphetamine Psychosis, and its Implication in Schizophrenia. Current Psychiatry Reviews. https://doi.org/10.2174/157340006778018111
630. Zhang, K., & Hashimoto, K. (2018). An update on ketamine and its two enantiomers as rapid-acting antidepressants. Expert Review of Neurotherapeutics. https://doi.org/10.1080/14737175.2019.1554434
631. Zoellner, L. A., Graham, B., & Bedard‐Gilligan, M. (2019). Trauma- and Stressor-Related Disorders. Routledge eBooks. https://doi.org/10.4324/9780429028267-10
632. Zuckerman, M. (2005). Psychobiological Methods. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511813733.003
633. Zutshi, A., Math, S. B., & Reddy, Y. C. J. (2007). Escitalopram in Obsessive-Compulsive Disorder. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0611c
634. Álvarez, E., & Viñas, F. P. (2010). Mirtazapine in combination..
635. Šakić, B., Babović, S., & Gajić, Z. (2014). Erythromycin-Induced Psychotic Decompensation in a Patient Affected by Paranoid Schizophrenic Psychosis. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology. https://doi.org/10.5455/bcp.20140802124414
636. Šostar, Z., Vodanović, M., Breitenfeld, D., Breitenfeld, T., Buljan, D., & Granić, R. (2009). Composers - Substance Abusers. Alcoholism and psychiatry research Journal on psychiatric research and addictions.
637. Šumarac-Dumanović, M., Micić, D., Macut, Đ. P., Kendereški, A., Zorić, S., Cvijović, G., & Pejković, D. (2002). Hipoglikemijski sindromi - dijagnostički i terapijski pristup i prikaz dva slučaja. ABC - časopis urgentne medicine.